

**Harvard Medical School
Curriculum Vitae**

Date Prepared: 6/7/2022
Name: Dost Öngür
Office Address: AB South 353
McLean Hospital
115 Mill Street
Belmont, MA 02478
Work Phone: 617 855 3922
FAX: 617 855 2895
E-mail: dongur@partners.org
Place of Birth: Istanbul, Turkey

Education:

1992	BA	Oberlin College
1994	MS in Neuroscience	Yale University
2000	MD/PhD in Neurobiology	Washington University in St. Louis

Post-Doctoral Training:

2000-2001	Medicine Internship	Massachusetts General Hospital/ Mt. Auburn Hospital
2001-2004	Resident in Psychiatry	Massachusetts General Hospital/ McLean Hospital

Faculty Academic Appointments:

2004-2006	Instructor in Psychiatry	Harvard Medical School
2006-2012	Assistant Prof. of Psychiatry	Harvard Medical School
2012-2017	Associate Prof. of Psychiatry	Harvard Medical School
2018-present	William P. and Henry B. Test Professor of Psychiatry	Harvard Medical School
2021	Visiting Scholar	Copenhagen Mental Health Center/ University of Copenhagen

Clinical Appointments

2004-2006	Assistant Psychiatrist	McLean Hospital
-----------	------------------------	-----------------

2006-2012	Associate Psychiatrist	McLean Hospital
2012-present	Psychiatrist	McLean Hospital

Administrative Appointments at Hospitals/Affiliated Institutions:

2005-2006	Assistant Director	Schizophrenia and Bipolar Disorder Program, McLean Hospital
2006-2009	Director	Schizophrenia and Bipolar Disorder Program, McLean Hospital
2009-2012	Clinical Director	Psychotic Disorders Division, McLean Hospital
2011-present	Director	Waverley Place Community Support Program
2012-present	Chief	Psychotic Disorders Division, McLean Hospital

Committee Service:

Local

2006-present	McLean Executive Committee – Patient Care Assessment Committee
2007-2017	MGH/McLean Adult Psychiatry Residency Steering Committee
2009-present	McLean Academic Steering Committee
2009-2013	Data Safety Monitoring Board - "Lamotrigine Therapy in the Treatment of Geriatric Bipolar Depression: An Evaluation of the Markers of Cerebral Energy Metabolism" Brent Forester (PI) – McLean Hospital
2010-2012	The President’s Cabinet – McLean Hospital
2011-2016	Co-chair McLean Hospital Psychiatry Residency Alumni Association
2011-present	Harvard Medical School Psychiatry Research Committee
2012-2017	Co-director Research Concentration Program of the MGH/McLean Adult Psychiatry Residency Program
2012-2016	Data Safety Monitoring Board – “Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders” Deborah Levy (PI) – McLean Hospital
2013	Fenna Krienen Ph.D. Dissertation Committee, Harvard University Department of Psychology
2014	Scientific Advisory Board for Early Psychosis Program, Boston Children’s Hospital Department of Psychiatry

2015-2018 Chair, Data Safety Monitoring Board (DSMB) – “Cognitive training in clinical high risk for psychosis” Christine Hooker (PI) – Harvard University

2015-2019 Harvard Catalyst CTSA KL2-CMerit Application Review Committee

2015-2018 Member, Harvard Medical School “Medical Student Promotion and Review” Committee (chaired by Dr. Grace Chang)

2016 Harvard University Undergraduate Senior Neurobiology Thesis evaluator for Melissa Yuan

2016-present Member, Scientific Advisory Board for Dauten Family Center for Bipolar Treatment Innovation at MGH

2017 Tova Gardin M.P.P. Medical School Honors Thesis Examiner, Harvard Medical School

2017 Brandeis University Undergraduate Science Festival mentor and evaluator for Alec Hoylan

2017-2019 Deputy Chair, Harvard Medical School Psychiatry Research Committee

2019-2021 Chair, Harvard Medical School Psychiatry Research Committee

2019 Member, McLean Hospital Child Psychiatry Research Director Search Committee

2019-2022 Harvard Medical School Promotions & Reappointments Committee – meets approximately monthly to review all academic promotions for the medical school

2021-22 Member, McLean Hospital Chief of Psychology Search Committee

2022 Member, Boston Children’s Hospital Neurology Faculty Search Committee

2022 Thesis Committee for Alejandro Szmulewicz ScD at T.H. Chan Harvard School of Public Health

National

2010 National Network of Depression Centers Bipolar Disorder Task Group

2012 Invited member at NIMH RDoC (Research Domain Criteria) Workshop on Arousal and Regulatory Mechanisms, Bethesda, MD

2014-16 Program Committee for the Annual Meeting of the Society of Biological Psychiatry (SOBP)

2015-17 Education and Training Committee of the American College of Neuropsychopharmacology (ACNP)

2015-present Brain and Behavior Research Foundation (NARSAD) Scientific Council

- 2016 Co-chair NIMH PhenX Early Psychosis Working Group [of the NIH’s “The PhenX project” (Consensus Measures for PHENotypes and eXposures)] – Chair of the Translational Research Measures sub-panel
- 2016-2017 Chair, Advisory Board for the National Psychosis Screening and Awareness Day, organized by Screening for Mental Health Inc.
- 2019 Member, DSMB – “OnTrack the Game” Lisa Dixon (PI) – Columbia University
- 2019-present EPINET National Steering Committee
- 2020-2022 Membership Committee of the ACNP
- 2020-present Chair, DSMB – “TRANCENDS Study” John Krystal (PI) – Yale University
- 2020 Vice President, American Psychopathological Association
- 2021 President-Elect, American Psychopathological Association
- 2022 President, American Psychopathological Association
- 2021-present Councilor-at-Large, SOBP
- 2022-present Integrated Network for Bipolar Disorder Steering Committee organized by Milken Institute
- 2022 Co-chair for Workshop Planning Committee, “Early Interventions for Psychosis” hosted by National Academies of Science, Engineering, and Medicine

International

- 2009 Invited expert to for The International Antipsychotic Clinically Equivalent and Recommended Dose (ACER - Dose) Study –international survey of clinician leader opinions in psychotic disorders; Nova Scotia, Canada
- 2015-2018 Steering committee member for the 2018 Biannual meeting of the International Early Psychosis Association (IEPA) meeting to take place in Boston, MA
- 2018 Member, Ersnt Strungmann Forum on Youth Mental Health, Frankfurt, Germany – 32 invited experts convened for a 5-day meeting which resulted in a book published by MIT Press
- 2019 Member, Global Mental Health Delivery for People with Severe Mental Illness, Dubai, UAE – 40 invited experts convened for 3-day meeting
- 2018-2020 Member, Publications Committee, Schizophrenia International Research Society (SIRS)
- 2020-present Member, Common Measures in Mental Health Science Governance Board (CMB) for the International Alliance of Mental Health Research Funders
- 2022-present Member, International Advisory Board for the Danish Risk and Resilience Study (VIA)
- 2022-present Member, Board of the Schizophrenia International Research Society (SIRS)

Professional Societies:

1992-1999	Society for Neuroscience
1992-1994	Phi Beta Kappa Academic Society
2002-2016	Member, American Psychiatric Association
2003-present	American Medical Association
2006-2010	International Society for Bipolar Disorder
2008-2012	Associate Member, American College of Neuropsychopharmacology
2009-present	Society of Biological Psychiatry
2012-2016	Member, American College of Neuropsychopharmacology
2016-present	Fellow, American College of Neuropsychopharmacology
2016-present	Member, American Psychopathological Association
2016-2019	Fellow, American Psychiatric Association
2019-present	Distinguished Fellow, American Psychiatric Association
2019-present	Member, Schizophrenia International Research Society

Grant Review:

National

2013	NIMH Special Emphasis Panel ZMH1 ERB-L (04) Biobehavioral Research Awards for Innovative New Scientists 3/27/2013
2013	Guest reviewer for VA Merit Review Panel MHBB (Mental Health and Behavior Biology)
2013	NIH ZRG1 RPHB-R (13)B Small Business Psycho/Neuropathology, Lifespan Development, and Science Education
2013	NIH ZRG1 RPHB-R (12)B Small Business Psycho/Neuropathology, Lifespan Development, and Science Education
2013	Guest reviewer for VA Merit Review Panel MHB (Mental Health and Behavior)
2014	NIMH Special Emphasis Panel ZMH1 ERB-L (01 P) Silvio O. Conte Centers for Basic or Translational Mental Health Research (P50) 10/28/2014
2014	Guest reviewer for VA Merit Review Panel MHB (Mental Health and Behavior) 11/20/2014
2015	Temporary Member NIH Developmental Brain Disorders (DBD) Study Section

- 2015 Guest reviewer for VA Merit Review Panel MHB (Mental Health and Behavior)
- 2015 NIMH Special Emphasis Panel ZMH1 ERB-C (08 S) Novel Assays to Address Translational Gaps in Treatment Development (UH2/UH3)
- 2015-2018 Standing member of the Veterans Administration Federal Advisory Committee (FACA) for the Mental Health and Behavior Panel (MHB)
- 2016 NIMH Special Emphasis Panel ZMH1 ERB-D (03 R) Emotional Regulation in Aging, 12/1/2016
- 2018 NIMH Special Emphasis Panel ZMH1 ERB-B (03): Addressing Suicide Research Gaps, 2/16/2018
- 2018 NIH Review Panel: Fogarty Global Brain Disorders Initiative, 3/1/2018

International

- 2008 Invited external reviewer for Johnson Foundation grant awards, Berne, Switzerland
- 2009 Invited external reviewer for Catalan Agency for Health Technology Assessment and Research (CAHTA) annual research award, Barcelona, Spain
- 2011 Invited external reviewer for the Ontario Mental Health Foundation annual research grant mechanism, Toronto, Ontario, Canada
- 2012 Invited external reviewer for the Canada Foundation for Innovation research grant program, Ottawa, Ontario, Canada
- 2014 Invited external reviewer for the Polish National Science Center OPUS grant mechanism
- 2015 Invited external reviewer for the British Medical Research Council (MRC) Fellowship grant mechanism
- 2015 Invited external reviewer for the Neurological Foundation of New Zealand grant project program
- 2016 Invited external reviewer for the Netherlands Organization for Health Research and Development (ZonMw) Veni program
- 2016 Invited external reviewer for the British Medical Research Council (MRC) Skills Development Fellowships grant mechanism
- 2017 Invited external reviewer for the Netherlands Organization for Health Research and Development (ZonMw) program

Editorial Activities:

- Ad hoc Reviewer (Selected journals from among many)

New England Journal of Medicine
Archives of General Psychiatry/JAMA Psychiatry
American Journal of Psychiatry
Molecular Psychiatry
Biological Psychiatry
Neuropsychopharmacology
Schizophrenia Research
Schizophrenia Bulletin
Bipolar Disorders
Psychiatry Research
Journal of Comparative Neurology
Journal of Clinical Psychiatry
Journal of Clinical Psychopharmacology
Neuroimage
Journal of Psychiatry and Neuroscience
Neuropsychobiology
Journal of Mental Health Policy and Economics

- Other Editorial Roles

2002- 2005	Assistant Editor	<i>Harvard Review of Psychiatry</i>
2004-2010	Advisory Board-Permanent Reviewer	<i>European Psychiatry</i>
2005-present	Associate Editor	<i>Harvard Review of Psychiatry</i>
2011-2018	Editorial Board member	<i>Biological Psychiatry</i>
2012-2013	Associate Editor (NOTE: became JAMA Psychiatry on 1/1/13)	<i>Archives of General Psychiatry</i>
2013-present	Editorial Board member	<i>Dusunen Adam Dergisi (Turkish)</i>
2013-2018	Editorial Board member	<i>Neuropsychopharmacology</i>
2013-2017	Associate/Deputy Editor (NOTE: was Archives of General Psychiatry until 12/31/12)	<i>JAMA Psychiatry</i>
2015-2018	Editorial Board member	<i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i>
1/1/2018-6/30/2018	Acting Editor	<i>JAMA Psychiatry</i>
7/1/2018-present	Editor-in-Chief	<i>JAMA Psychiatry</i>
7/1/2019-present	Editorial Board	<i>Psychiatric Annals</i>

Honors and Prizes:

1997	Travel award; Affective Neuroscience Symposium; Madison, WI
2003	Solomon Research Award, Dept. Psychiatry, HMS; Boston, MA
2003	APA Travel Award to the Research Colloquium for Junior Investigators; San Francisco, CA
2003	APA/Astra Zeneca Young Minds in Psychiatry Award
2004	Laughlin Fellow, American College of Psychiatrists; Miami Beach, FL
2004	Dupont-Warren Research Fellowship Award, Dept. Psychiatry, HMS; Boston, MA
2004	NARSAD Young Investigator Award
2004	Thomas P. Hackett Award, Dept. Psychiatry Massachusetts General Hospital
2004	Laughlin Award at Graduation, McLean Hospital
2005	Clinical Investigator Training Program Fellowship Award, MIT/HMS; Boston, MA
2006	ACNP Young Investigator Memorial Travel Award
2007	Phillip L. Isenberg Teaching Award, MGH-McLean Psychiatry Residency Program
2008	Leadership Development for Physicians and Scientists, Harvard Medical School
2008	Alfred Pope Award for research, McLean Hospital
2008	Best Research Paper Award, East Meets West Psychiatry meeting, Antalya, Turkey
2010	Harvard Medical School Young Mentoring award – nominated by mentees, selected by HMS
2010	Selected for Best Doctors in America 2011-2012-2013 databases
2011	Jonathan F. Borus Outstanding Early Career Educator Award in Medical Student Education, Harvard Medical School Dept. of Psychiatry
2012	Psychopharmacology Supervision Award, MGH-McLean Psychiatry Residency Program
2013	Vision of Excellence award, McLean Hospital
2015-2016	Best Doctors in the U.S. Database – voted in by peers
2016	Ed Messner Teaching Award, MGH-McLean Psychiatry Residency Program – voted on by PGY2 residents
2017	Anne Cataldo Mentoring Award, McLean Hospital

2018	Massachusetts Psychiatric Society 2018 Outstanding Psychiatrist Award for Research
2018	Harry Stack Sullivan award from Sheppard Pratt Hospital, Baltimore, MD
2019	Kempf Award, American Psychiatric Association

Report of Funded and Unfunded Projects

Funding Information

Past Research Support

2004-2005	PI	APA-Astra Zeneca Young Minds in Psychiatry Award	\$45,000
Type: Fellowship Award			
Title: The role of the anterior cingulate cortex in cognitive interference tasks in schizophrenics			
Goals: Use functional MRI to study cognitive interference tasks in schizophrenia			
2004-2006	PI	Harvard Medical School	\$45,000
Type: Dupont-Warren Fellowship Award			
Title: Neural correlates of cognitive dysfunction in schizophrenia and bipolar disorder			
Goals: Use functional MRI to study transitive inference in bipolar disorder and schizophrenia			
2005-2007	PI	Clinical Investigator Training Program, Harvard/MIT	\$110,000
Type: Fellowship Award			
Title: Magnetic resonance spectroscopy studies on cellular function and neurotransmission in bipolar disorder			
Goals: Development of ¹³ C magnetic resonance spectroscopy approaches to study bipolar disorder			
2004-2007	PI	NARSAD	\$60,000
Type: Young Investigator Fellowship Award.			
Title: The role of the medial temporal lobe and prefrontal cortex in paired object recognition in subjects with schizophrenia and bipolar disorder			
Goals: Use functional MRI to study the medial temporal lobe in paired object recognition in schizophrenia			
2007-2011	PI	NIMH	\$829,995
Type: K23 Career Development Award.			
Title: MRS Studies of glutamate and GABA in bipolar disorder			
Goals: Use magnetic resonance spectroscopy to examine glutamate and GABA levels in manic, euthymic, and depressed phases of bipolar disorder			
2007-2011	PI	Jim and Pat Poitras Foundation	\$430,000
Type: Research Award			

Title: Riluzole and Ampicillin in the Treatment of Bipolar Depression: A Study of the Association Between Clinical Response and Change in Brain Glutamate Levels as Measured by Proton Magnetic Resonance Spectroscopy

Goals: Study the effect of two innovative glutamatergic treatments for bipolar depression in conjunction with *in vivo* measures of brain glutamate using magnetic resonance spectroscopy

2006-2011 PI Louise Crane Foundation \$48,000

Type: Research Award

Title: Carbon-13 Magnetic resonance spectroscopy in bipolar disorder and schizophrenia

Goals: Development of ¹³C magnetic resonance spectroscopy approaches to study schizophrenia and bipolar disorder

2010-2011 PI NIMH \$50,000

Type: ARRA Supplement to K23 Career Development Award.

Title: MRS Studies of glutamate and GABA in bipolar disorder

Goals: Use magnetic resonance spectroscopy to examine glutamate and GABA levels in manic, euthymic, and depressed phases of bipolar disorder

2010-2013 Subcontractor (PI: Schmahmann) Baer Foundation \$9,360

Type: Foundation Award

Title: Transcranial Magnetic Stimulation in the Treatment of Patients with Schizophrenia

Goals: Assessment of Transcranial Magnetic Stimulation (TMS) in the treatment of patients with schizophrenia

2011-2012 PI Rules Based Medicine Inc. \$58,480

Type: Research Contract

Title: Diagnostic Assessment of Psychotic Disorders Using Serum Samples

Goals: Diagnostic assessment of psychotic disorders using serum samples.

2012-2014 PI NIMH \$305,936

Type: 1R21MH096107

Title: Genetics of glutamatergic neurotransmission

Goals: Use magnetic resonance spectroscopy and genetics to examine glutamatergic neurotransmission in healthy individuals

2013-2015 PI Brain Behavior Research Foundation (NARSAD) \$92,400

Type: Foundation Award

Title: Examination of Brain Energy Production in First Episode Schizophrenia Using a Novel Neuroimaging Approach

Goals: Collect brain energetics data in first episode schizophrenia

2011- 2016 PI NIMH \$1,165,240
Type: 1R01MH094594-01
Title: Probing the white matter in schizophrenia using novel MRS techniques
Goals: Use magnetic resonance spectroscopy to examine white matter abnormalities in schizophrenia.

2008-2016 PI Taplin Foundation \$260,000
Type: Research Award
Title: Neuroimaging-genetics combination analysis in psychotic disorders
Goals: Examine the influence of genetic variation on brain phenotypes in psychotic disorders through the collection of structural and functional MRI and genetics data from 300 subjects with schizophrenia or bipolar disorder

2014-2018 PI NIMH \$600,000
Type: 1R01MH105388-01
Title: An MRI based in vivo measure of glutamatergic synaptic neurotransmission
Goals: The goal is to develop a noninvasive MRI-based technique for quantifying synaptic glutamate release in an animal model at ultra-high magnetic field.

2017-2018 PI (assumed after death of Dr. Yue Chen) NIMH \$385,720
Type: R01MH096793-05
Title: Face processing systems in schizophrenia spectrum disorders
Goals: The goal is to investigate the nature of and the brain mechanisms responsible for the face perception problem in the schizophrenia spectrum. We use state of the art psychophysical and neuroimaging approaches to evaluate perceptual and cortical responses when patients perform face detection, face identity discrimination, and face emotion discrimination tasks.

2014-2018 Contact PI (MPI: Hsu) NIMH \$2,495,856
Type: 1R01MH104560-01
Title: Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients
Goals: The goal is to carry out a clinical trial of a low, fixed dose intervention of a combined statin-ACE inhibitor medication for metabolic syndrome in severe mental illness.

2019-2020 Öngür/Du (PI's)
Type: Harvard Brain Science Initiative
Title: NR Supplementation to correct Redox Imbalance in Psychotic Disorders
Goals: This project's goal is to assess Nicotinamide Riboside supplementation in bipolar disorder using 31P MRS.

2015-2020 PI NIMH \$592,500
Type: 1K24MH10449-01
Title: Research and mentoring on brain and peripheral bioenergetics in schizophrenia
Goals: The goal is to mentor junior investigators in patient oriented research in schizophrenia and to deepen the PI's expertise in studies of bioenergetics in schizophrenia.

2017-2020 Du (PI) \$275,000
Type: R21MH114020

Title: Oxidative Stress in First Episode Schizophrenia Assessed in vivo Using NAD+ and NADH Measurement

Goals: The current study aims to develop an in vivo biomarker targeted on oxidative stress in schizophrenia patients. In this proposal, we will utilize in vivo 1H- and 31P-MRS to directly quantify both antioxidant level-GSH and redox state (NAD+/NADH) in 1st episode schizophrenia patients in the same experiment session and validate whether reduced antioxidant GSH level is associated with the reduced redox state in schizophrenia.

Role: Co-Investigator

Current Research Support

2016-2021 PI National Alliance for Mental Illness (NAMI) \$300,000

Type: Unger Family Fellowship

Title: Assessing the impact of an open-communication model on patient-centered outcomes

Goals: The goal is to implement a novel treatment model on an inpatient unit caring for patients with psychotic disorders.

2016-2020 Co-I (PI: Shenton) NIMH \$44,914 (subcontract)

Type: U01MH109977-01

Title: Human Connectome Project for Early Psychosis

Goals: The goal is to recruit and scan 300 patients with first episode psychosis (schizophrenia, schizoaffective disorder, and bipolar disorder with psychosis) and provide high quality data for the NIMH's Human Connectome in Disease project.

2019-2023 Öngür/Hsu/Hernan (PI's) NIMH \$6,700,000

Type: 1P50MH115846

Title: Laboratory for Early Psychosis Research (LEAP)- Administrative Core

Goals: This project develops the collaborations, data systems, and methods necessary to form a state-wide Laboratory for Early Psychosis Research, aka the LEAP Center, to enhance our understanding of heterogeneity in patient outcomes and treatment approaches in first episode psychosis.

Role: Administrative Core Lead

2019-2023 Öngür/Hsu/Hernan (PI's) NIMH \$6,700,000

Type: 1P50MH115846

Title: Laboratory for Early Psychosis Research (LEAP)- Project 2

Goals: This project develops the collaborations, data systems, and methods necessary to form a state-wide Laboratory for Early Psychosis Research, aka the LEAP Center, to enhance our understanding of heterogeneity in patient outcomes and treatment approaches in first episode psychosis.

Role: Project Lead

2018-2023 Niznikiewicz (PI)

Type: 1R61MH113751

Title: Real-time fMRI Neurofeedback as a Tool to Mitigate Auditory Hallucinations in Patients with Schizophrenia

Goals: The goal of this application is to demonstrate the efficacy of a novel method of AH reduction, real time fMRI neurofeedback (rt-fMRI).

Role: Co-Investigator

2019-2023 Brady (PI)

Type: 1R01MH116170

Title: Network Mediation of Experiential and Expressive Deficits in Psychotic Disorders

Goals: The goal of this project is to determine if network connectivity determines negative symptoms in psychosis.

Role: Subaward PI

2019-2023 Du/Öngür (PIs)

Type: 1R01MH114982

Title: Molecular Mechanisms and Biomarkers for Disease Progression from Prodrome to Early Psychosis

Goals: The goal of this project is to collect proton and phosphorus MRS data on oxidative balance in a cohort of first episode psychosis patients, their relatives, and matched healthy controls. The cohort will be followed over time and abnormalities in oxidative balance will be correlated with cognitive and functional outcomes.

Report of Local Teaching and Training

Undergraduate courses

- 2009 Guest lecturer on “Schizophrenia” in Experience-Dependent Brain Development (MCB146) taught by Prof. Takao Hensch at Harvard University (2 hours/year)
- 2013-2017 Preceptor for Wintersession: Perspectives on Mental Illness taught by Prof. Takao Hensch at Harvard University (4 hours/year)
- 2015-2022 Guest lecturer on “Schizophrenia” in Experience-Dependent Brain Development (MCB146) taught by Prof. Takao Hensch at Harvard University (2 hours/year)

Medical school courses

- 2003-2006 Harvard Medical School core clerkship in psychiatry, monthly lectures to rotating 3rd year medical students on Schizophrenia; Bipolar Disorder (8 hours/year)
- 2008-2018 Annual HST core psychiatry lecture on Schizophrenia (2 hours/year)
- 2021 HST core psychiatry lecture on Schizophrenia (1 hour/year)

2009-2016 Annual HMS core 2nd year psychiatry (PS 700M.J) lecture on Schizophrenia (2 hours/year)

Graduate medical courses

2003 MGH/McLean orientation didactic series for junior psychiatry residents on antipsychotics and mood stabilizers (4 hours/year)

2003-present Didactic series on “Schizophrenia and Bipolar Disorder” for junior psychiatry residents; Quarterly lectures, topics vary but some examples are: Mood Stabilizers; Evaluating Medication Effects; Genetics; Epidemiology; Brain Abnormalities in Psychosis; Brain Abnormalities in Mood Disorders (16 hours/year)

2004- 2007 Neuroscience Curriculum coordinator for the MGH/McLean Adult Psychiatry residency; organize, teach and/or attend a series of 29 introductory lectures for residents in their second year of training and a series of 15 advanced lectures for residents in their fourth year of training. (30 hours/year)

2006-2007 Quarterly lecture on “Schizophrenia” for junior psychiatry residents at the Erich Lindemann Mental Health Center (4 hours/year)

2009 MIT graduate course in Neurobiology of Disease – visiting speaker (2 hours/year)

2015-present “Big Picture Rounds” for MGH/McLean Adult Psychiatry residents – once every 6 weeks I interview a patients and discuss implications of the case. About 4 residents attend each session. (16 hours/year)

2016 Invited speaker at Dept. Mental Health training for residents of all psychiatry training programs in the state of Massachusetts: “First episode psychosis: challenges and opportunities”, Worcester, MA (4 hours/year)

2017 Lecture on “Clinical Research in Schizophrenia” at the Harvard Medical School Neuroscience Quarter Course: Neurobiology of Psychiatric Disease (2 hours/year)

2018-present Annual lecture on “Neurobiology of Schizophrenia” for PGY2 residents in the BWH Adult Psychiatry Program

2019 Lecture on “Clinical Research in Schizophrenia” at the Harvard Medical School Neuroscience Quarter Course: Neurobiology of Psychiatric Disease (2 hours/year)

Supervisory and training responsibilities

Clinical Supervision

2004-2008 Harvard Medical School core clerkship in psychiatry, preceptor for rotating medical students (16 hours/year)

2004-present Supervision of second year residents in the Schizophrenia and Bipolar Disorder Unit at McLean Hospital (1-2 weeks/year)

2006- 2008 McLean Hospital Psychopharmacology Consultation Service, attending psychiatrist (1 month/year)

2009-2013 Psychopharmacology supervision of third year residents (1 hour/week)

Research Supervision

2004-present Data acquisition/processing/analysis training on 3T and 4T MRI human scanners at the Brain Imaging Center at McLean Hospital – approximately 40 supervisees

2005-present Supervision of structured clinical interviews by PhDs/MDs/research assistants – approximately 60 supervisees

2009-present Preceptor for the Training in Drug Abuse and Brain Imaging Training Program (T32 PI: Lukas)

2010-2011 Thesis Director for Mariya Gaber, M.Biotech. candidate at Harvard Extension School. Thesis title “Efficient management and recruitment of study sites to a large prospective study on imaging modalities-could we have predicted successful and unsuccessful sites”

2011-present Primary mentor for NARSAD Young Investigator awards for Mei Hua Hall Sc.D., Ann Shinn M.D., Cagri Yuksel M.D., Fei Du Ph.D., Virginie-Anne Chouinard M.D., Lauren Moran M.D., Michael Murphy M.D. Ph.D., Alexis Whitton Ph.D., Matthew Hutchinson Ph.D., Xi Chen Ph.D. – dates vary

2012-present Primary mentor for NIMH K23 awards Ann Shinn M.D., Justin Baker M.D. Ph.D., Roscoe Brady M.D. Ph.D., Lauren Moran M.D., Danhong Wang M.D., Virginie-Anne Chouinard M.D., Michael Murphy M.D., Ph.D., Cagri Yuksel M.D., Julie McCarthy Ph.D. – dates vary

2013-2017 Primary mentor for NIMH K01 award for Mei Hua Hall Sc.D.

2012-present Site mentor for the Hauser Clinical Research Training Program (T32 PIs: Shenton, Kubicki)

2013-present Preceptor for the Pamela Sklar - Stanley Center Fellowship at the Broad Institute of Harvard/MIT

2014 Primary mentor for KL2-MERIT award from Harvard Catalyst (CTSA) for Justin Baker M.D. Ph.D.

2016-2018 Primary mentor for Stanley Center Fellowship for Michael Murphy M.D. Ph.D.

Formally supervised trainees

- 2007-present Kathryn Eve Lewandowski, Ph.D.
Post-doctoral fellow (now Assistant Professor at Harvard Medical School – mentor on K23 award)
- 2007-2012 Anita Bechtholt, Ph.D.
Post-doctoral fellow (became Assistant Professor at Harvard Medical School, now Program Officer at NIAAA)
- 2008-present Justin Baker, M.D., Ph.D.
Psychiatry resident (now Assistant Professor at Harvard Medical School – co-primary mentor on K23 award)
- 2008-present Ann Shinn, M.D.
Chief Resident (now Assistant Professor at Harvard Medical School – co-primary mentor on K23 award)
- 2009-2010 Roscoe Brady, M.D., Ph.D.
Chief Resident (now Assistant Professor at Harvard Medical School – co- primary mentor on K23 award)
- 2009-present Fei Du, Ph.D.
Associate Professor at Harvard Medical School (mentor on NARSAD award)
- 2010-2011 Joseph Stoklosa, M.D.
Psychiatry Chief Resident (now Assistant Professor at Harvard Medical School)
- 2012-present Mei Hua Hall, Sc.D.
Associate Professor at Harvard Medical School (co- primary mentor on K01 award)
- 2012-present Cagri Yuksel, M.D.
Instructor (mentor on NARSAD award)
- 2013-2017 Gagan Joshi, M.D.
Instructor (advisor on K23 award)
- 2014-present Virginie-Anne Chouinard M.D.
Instructor (mentor on HMS Dupont-Warren fellowship)
- 2014-present Lauren Moran, M.D.
Assistant Professor (mentor on NARSAD and co- primary on K23 award)

- 2014 Matthew Hutchinson Ph.D.
Instructor (mentor on NARSAD award)
- 2015 Alexis Whitton Ph.D.
Instructor (mentor on NARSAD award)
- 2016-present Michael Murphy M.D., Ph.D.
Assistant Professor (mentor on Stanley Center Fellowship at the Broad Institute)
- 2017-present Danhong Wang M.D.
Instructor (co-primary mentor on K01 award)
- 2019-present Emily Carol PhD
Instructor
- 2019-present Nicole Benson MD
Instructor
- 2019-present Julie McCarthy PhD
Instructor
- 2020-present Zachary Millman PhD
Postdoctoral fellow

Formal teaching of peers

- 2006-present Annual lecturer on “Antipsychotics” at McLean Psychiatry Update Course, Boston, MA
- 2006-2008 Annual lecturer on “Functional Neuroanatomy” at MGH Board Review Course, Boston, MA
- 2006-2012 Annual lecturer on “Neurobiology of Schizophrenia” at MGH Psychopharmacology Course, Boston, MA
- 2011 Invited lecturer on “Psychopharmacologic management of psychotic disorders” at MGH Virtual Grand Rounds Summer series
- 2012-2015 Annual lecturer on “Mood stabilizers” at McLean Psychiatry Update Course, Boston, MA
- 2012 Lecturer on “Depression: unipolar, bipolar, and psychotic” at McLean CME Course on Depression, Anxiety, and Stress; Boston, MA

- 2013 Invited lecturer at Harvard Catalyst CTSA Neuroimaging Course: “Magnetic Resonance Spectroscopy”
- 2013-2015 Annual lecturer on “Neurobiology of Schizophrenia and Bipolar Disorder” at MGH Psychopharmacology Course, Boston, MA
- 2014 Lecturer on “Depression: unipolar, bipolar, and psychotic” at McLean CME Course on Depression, Anxiety, and Stress; Boston, MA
- 2014 Lecturer on “Novel Treatments in Schizophrenia” at HMS/MGH CME Course for visiting Brazilian psychiatrists, Boston, MA
- 2015 Lecturer on “Assessing and Managing Metabolic Risk in Bipolar Disorder and Schizophrenia” at the MGH Colloquium on Challenges in the Treatment of Mood Disorders and Schizophrenia
- 2015 Invited lecturer on “Clinical Neuropsychopharmacology: from Neurobiology to Practice” at the Annual Winter Symposia by the New England Educational Institute, Marco Island, FL
- 2015 Invited lecturer on “Neurotransmitters and Receptors” at MGH Virtual Board Review series
- 2011-2016 Annual invited lecturer on “Clinical Neuropsychopharmacology: from Neurobiology to Practice”, a weeklong course at the Annual Cape Cod Summer Symposia by the New England Educational Institute, Eastham, MA

Local invited presentations

- 2008 Grand Rounds, McLean Hospital: “Findings from CATIE and STEP-BD”
- 2009 Clinical Investigator Training Program visiting faculty speaker
- 2010 Invited speaker – “Metabolic Syndrome and Antipsychotic Medications” Partners Physicians Day
- 2010 Grand Rounds, McLean Hospital: “Basic research advances and clinical implications in schizophrenia and bipolar disorder”
- 2010 Panel participant at Psychiatry Medical Student Education Day, Harvard Medical School
- 2010 Brigham and Women’s Hospital Behavioral Neurology Group seminar speaker

- 2011 Grand Rounds, MGH Combined Neuroscience Series (Neurosurgery, Neurology, Psychiatry), Boston, MA: “Magnetic resonance spectroscopy studies in psychiatric disorders”
- 2011 Psychiatric Neuroscience Laboratory, Brigham and Women’s Hospital, Boston, MA: “Probing white matter abnormalities in schizophrenia using MRS”
- 2011 Center for Depression Anxiety and Stress, McLean Hospital:”MRS studies in schizophrenia and bipolar disorder”
- 2011 Psychiatric Neuroscience and Genetics Group, MGH, Boston, MA: “MRS studies of schizophrenia and bipolar disorder”
- 2012 Invited Speaker, Harvard University Conti-CBS Colloquium on Mental Health: “Neurobiology of Schizophrenia”
- 2013 Grand Rounds, Harvard University Health Services: “Psychopharmacologic management of bipolar disorder”
- 2013 Invited Psychopharmacology Rounds speaker – Cambridge Health Alliance, Somerville, MA
- 2013 Invited panel co-leader (with Tracey Milligan MD), Harvard Medical Student Psychiatry Teaching Symposium: “Toward an integrated mind-brain-behavior curriculum”, Cambridge, MA
- 2015 Grand Rounds, McLean Hospital: “New treatments in psychotic disorders”
- 2015 Grand Rounds, MGH Combined Neuroscience Series (Neurosurgery, Neurology, Psychiatry), Boston, MA: “³¹P Magnetic resonance spectroscopy studies of brain bioenergetics in psychotic disorders”
- 2016 Invited Speaker, Harvard Brain Initiative Symposium on Bipolar Disorder: “Current challenges in translational research in bipolar disorder”
- 2016 Grand Rounds, Massachusetts Mental Health Center: “Cardiovascular Mortality in Serious Mental Illness: the FITNESS Study”
- 2016 Psychopharmacology Series, Cambridge Health Alliance: “New Drug Development in Schizophrenia”
- 2016 Invited speaker at the Translational Neuroscience Center at Boston Children’s Hospital: “MRS studies of brain bioenergetics in psychotic disorders”, Boston, MA

- 2016 Invited speaker and panel co-leader (with Suzannah Zimmet MD) at Early Intervention in Psychosis Symposium, Massachusetts Mental Health Center, Boston, MA
- 2016 Discussant at the “R to R Symposium” held by the Harvard Catalyst for first-time R01 awardees (2.5 hour symposium, 12 presenters, 20 attendees), Boston, MA
- 2016 Grand Rounds, Combined Longwood Psychiatry program: “MRI Studies of bioenergetics abnormalities in psychotic disorders”, Boston, MA
- 2017 Grand Rounds, McLean Hospital: “Antipsychotic polypharmacy”, Belmont, MA
- 2017 Invited Speaker, Massachusetts Mental Health Center Annual Early Psychosis Conference: “The NIMH-PhenX Initiative”, Boston, MA
- 2017 Graduation Address, Harvard South Shore Psychiatry Residency Program, Cambridge, MA
- 2019 Grand Rounds, McLean Hospital, jointly with Bruce Cohen M.D. Ph.D.: “Crossroads in treatment development in psychotic disorders”, Belmont, MA
- 2021 Grand Rounds, North Shore Medical Center, “Update on Bipolar Disorder Treatments”, Salem, MA (VIRTUAL)
- 2021 Grand Rounds, McLean Hospital, jointly with Brad Ruzicka M.D. Ph.D.: “Glutamate and GABA mechanisms in schizophrenia”, Belmont, MA (VIRTUAL)

Report of Regional, National and International Invited Teaching and Contributions
 (No presentations below were sponsored by outside entities)

Regional

- 2003 The structure and function of prefrontal cortex
 Invited lecturer for tape-recorded “Practical Reviews in Psychiatry” series edited by Drs. Robert Abernethy, Andrew Brotman, Donald Goff
- 2004 Social Work Grand Rounds at Salem Hospital, Salem, MA: “Bipolar Disorder”; “Schizophrenia”
- 2007 Invited Psychopharmacology Rounds speaker – Cambridge Health Alliance, Somerville, MA
- 2009 Featured in “The Carlat Report” – a psychopharmacology review for psychiatrists

- 2009 Boston Neuropsychiatric Society interview and presentation on Schizophrenia
- 2011 Grand Rounds, North Shore Medical Center Dept. of Psychiatry, Salem, MA: “Psychopharmacology of antipsychotic medications”
- 2012 Invited Speaker for the Annual Meeting of the Mental Health Legal Advisors Committee in Boston: “The anatomy of a commitment”
- 2012 Grand Rounds, North Shore Medical Center Dept. of Psychiatry, Salem, MA: “Antipsychotic medications”
- 2013 Social Work Grand Rounds at Salem Hospital, Salem, MA: Antipsychotic Medications
- 2014 Grand Rounds, University of Massachusetts Medical School: “Novel Therapies in Schizophrenia”, Worcester, MA
- 2016 Grand Rounds, Bedford VA Hospital, Bedford, MA: “Novel therapies in schizophrenia”
- 2018 Invited Presentation at the Sino-American Pharmaceutical Association – New England chapter: “Unmet needs in schizophrenia drug development”
- 2019 Panel speaker at the Dept Mental Health symposium on Early Psychosis Care, Westford, MA
- 2020 Presenter: “Bipolar Disorder 101” for the Harvard Brain Initiative, Boston, MA (VIRTUAL)
- 2020 Organizer and co-Host with the Department of Mental Health for “First Episode Psychosis Statewide Strategy Meeting” on Nov 5th 2020 (VIRTUAL)
- 2021 Organizer and co-Host with the Department of Mental Health for the second “First Episode Psychosis Statewide Strategy Meeting” on Nov 9th 2021 (VIRTUAL)
- 2022 Invited presentation for Neumora Inc.: “Neuroimaging studies in early psychosis” (VIRTUAL)

National

- 2007 Grand Rounds–Vanderbilt University Department of Psychiatry, Nashville, TN
- 2009 Grand Rounds– University of Utah Medical School Department of Psychiatry, Salt Lake City, UT

- 2009 Grand Rounds - William K. Warren Jr. Frontiers in Neuroscience Conferences at Laureate Hospital, Tulsa, OK
- 2009 Keynote address on “Antipsychotic Medications” at the Florida Psychiatric Society annual meeting, Orlando, FL
- 2010 Invited presentation – Price/Thach Symposium, Washington University Medical School, St.Louis, MO
- 2010 Invited presentation – Laboratory of Neuro-Psychiatric Imaging (Dr. Kelvin Lim) – University of Minnesota, Minneapolis, MN
- 2010 Panel presentation “*In vivo* evidence for glial cell dysfunction in mood disorders” at the Annual Meeting of Society of Biological Psychiatry (SOBP), New Orleans, LA
- 2011 Panel presentation “Glutamate abnormalities in bipolar disorder” at the Annual Meeting of the NIMH National Conference of the Drug Evaluation Unit (NCDEU), Boca Raton, FL
- 2011 Psychiatric Neuroscience Seminar: “MRS studies in schizophrenia and bipolar disorder”, University of Pittsburgh, Pittsburgh, PA
- 2012 Invited speaker “Antipsychotic medications” at the Annual Meeting of the Society of Forensic Toxicologists, Boston, MA
- 2013 Invited speaker “Recovery: the new mental health paradigm” at the Annual Meeting of the Association of Health Care Journalists, Boston, MA
- 2013 Panel speaker “Frontal-subcortical circuits in psychosis and mood” at the Annual Meeting of the American Neuropsychiatric Association (ANPA), Boston, MA
- 2013 Panel speaker “MRS studies of glutamate and GABA in schizophrenia” at the SOBP annual meeting, San Francisco, CA
- 2013 Panel speaker “Outreach and engagement in a community psychiatry program” at the American Psychiatric Association (APA) annual meeting, San Francisco, CA
- 2014 Panel speaker “Neuroimaging studies of white matter in schizophrenia” at the SOBP annual meeting, New York City, NY
- 2014 Invited speaker: “Neuropathology and neuroimaging studies in mood disorders” at the MGH Preceptorship for Janssen executives, Boston, MA

- 2015 Invited lecturer on “Schizophrenia and bipolar disorder” for Audio Digest Neurology Review; audio recording for nation-wide distribution by the Audio Digest Foundation
- 2015 Invited Speaker: “MRI Studies of bioenergetics in psychotic disorders”, Legacy Research Institute and Dow Neurobiology Laboratories, Portland, OR
- 2015 Panel speaker “MRI studies of brain bioenergetics in schizophrenia: Implications for plasticity” at the ACNP annual meeting, Hollywood, FL
- 2015 Special seminar: “Neuroimaging studies of psychotic disorders: What have we learned?” University of Southern California Department of Psychiatry, Los Angeles, CA
- 2016 Invited speaker: “Dynamic evolution of neuroimaging abnormalities in schizophrenia” at the American PsychoPathological Association (APPA), New York City, NY
- 2016 Invited speaker: “MRI studies of brain bioenergetics in psychotic disorders” at Yale University Clinical Psychology speaker series, New Haven, CT
- 2016 Panel speaker “GABAergic abnormalities and their implications in bipolar disorder and schizophrenia” at the SOBP Annual Meeting, Atlanta, GA
- 2016 Panel chair “Neuroimaging: Clinical Trials” at the SOBP Annual Meeting, Atlanta, GA
- 2016 Annual Samuel Guze Lecture “Bioenergetic abnormalities in psychotic disorders” at Washington University Medical School, St. Louis, MO
- 2016 Panel Chair “Oxidative dysregulation in schizophrenia” at the ACNP Annual Meeting, Hollywood, FL
- 2017 Grand Rounds “MRS studies of bioenergetic abnormalities in psychotic disorders” at Mt. Sinai Medical School, New York, NY
- 2017 Grand Rounds “MRS studies of bioenergetics abnormalities in psychotic disorders” at University of California Davis, Dept. of Psychiatry, Davis, CA
- 2017 Grand Rounds “³¹P MRS studies of bioenergetics in psychotic disorders” at Vanderbilt University Medical School Dept. of Psychiatry, Nashville, TN
- 2017 Panel presentation “Bioenergetic abnormalities in early phase psychotic disorders” at the Annual Meeting of the Association for Psychological Science, Boston, MA

- 2018 Harry Stack Sullivan lecture at Sheppard-Pratt Hospital “Neurobiology and new drug development in schizophrenia”, Baltimore, MD
- 2018 Panel speaker “MRS studies of white matter abnormalities in schizophrenia” at the SOBP Annual Meeting, New York City, NY
- 2019 Keynote speaker “Big Data – Opportunities for Early Intervention in Psychotic Disorders” at the Washington D.C. Psychiatric Society Annual Meeting, Washington D.C.
- 2019 Guynn lecture “Bioenergetic abnormalities in psychotic disorders” at the Dept. of Psychiatry at University of Texas at Houston
- 2019 Keynote speaker “First Episode Affective Psychosis” at the Early Psychosis pre-meeting at the Institute for Psychiatric Services annual meeting, New York City, NY
- 2019 Grand Rounds “Presenting and publishing your work in academic psychiatry” at Pine Rest Hospital, Michigan State University Medical School, Grand Rapids, MI
- 2019 Grand Rounds “Magnetic Resonance Spectroscopy studies of psychotic disorders” at Columbia University Medical School, Department of Psychiatry, New York City, NY
- 2020 Grand Rounds “Magnetic Resonance Spectroscopy studies of brain bioenergetics in psychotic disorders” at Zucker Hillside Hospital, Queens, NY
- 2020 Research Seminar “Magnetic Resonance Spectroscopy studies of white matter in psychotic disorders” at Zucker Hillside Hospital, Queens, NY
- 2020 Residency seminar “Presenting and publishing your work in academic psychiatry” at University of Texas Southwestern, Dallas, TX (VIRTUAL)
- 2020 Invited speaker “Psychopharmacology Management of Early Psychosis During the COVID-19 Pandemic” in the Third National Conference on Advancing Early Psychosis Care in the United States by the American Psychiatric Association (VIRTUAL)
- 2020 Panel speaker “Bioenergetic Abnormalities in Psychotic Disorders” at the Annual Meeting of the ACNP (VIRTUAL)
- 2021 Distinguished Psychiatrist Lecture “First Episode Psychosis and Severe Mental Illness” at the Annual Meeting of the American Psychiatric Association (VIRTUAL)

- 2021 Grand Rounds “Magnetic Resonance Spectroscopy Studies in Psychotic Disorders”, Stonybrook University Department of Psychiatry (VIRTUAL)
- 2021 Ken Altshuler Grand Rounds “First Episode Psychosis: Clinical and Research Debates”, University of Texas Southwestern Department of Psychiatry (VIRTUAL)
- 2021 Panel speaker “LEAP – MAPNET Collaboration to Enhance First Episode Care in Massachusetts” at the Annual Psychosis Conference hosted by University of California, Davis (VIRTUAL)
- 2021 Grand Rounds “Magnetic Resonance Spectroscopy Studies of Brain Bioenergetics in Bipolar Disorder”, University of Utah Department of Psychiatry (VIRTUAL)
- 2021 Research Semina Speaker “Imaging studies in early psychosis”, Ohio State University EPICENTER Clinic (VIRTUAL)
- 2021 Conte Center Seminar Series “Magnetic Resonance Spectroscopy Studies of Brain Bioenergetics in Psychotic Disorders”, Maryland Psychiatric Research Center/University of Maryland (VIRTUAL)
- 2022 Invited speaker on “Bioenergetic abnormalities in psychosis” in the NIMH Workshop “Nonaffective Psychosis in Midlife and Beyond” (VIRTUAL)
- 2022 Resident-Invitational Grand Rounds speaker “Clinical Research in Early Psychosis”, Washington Univ. in St. Louis Department of Psychiatry (VIRTUAL)
- 2022 Grand Rounds: “First Episode Psychosis and the EPINET Consortium”, University of New Mexico School of Medicine (VIRTUAL)
- 2022 Charles and Jacqueline Rivasas Memorial Lecture and Grand Rounds: “Translational and Clinical Research in Early Psychosis”, Dartmouth Medical School Department of Psychiatry, Lebanon, NH (VIRTUAL)
- 2022 Grand Rounds “Clinical Research in Early Psychosis”, University of Washington, Seattle, WA (VIRTUAL)

International

- 2003 Invited speaker at featured panel “Tics, compulsions and the basal ganglia”; Annual Meeting of the Turkish Psychiatry Association, Antalya, Turkey: “Functional neuroanatomy of the basal ganglia” (in Turkish)
- 2008 Invited speaker on “Bipolar Disorder, Schizoaffective Disorder, Schizophrenia” in “East Meets West Psychiatry Conference”, Antalya, Turkey

- 2010 Invited speaker on “MRS studies of glutamatergic neurotransmission in clinical trials” in “Biomarkers in Clinical Trials”, Sernhac, France
- 2011 Panel presentation “Glutamate abnormalities in bipolar disorder” at the Annual Meeting of the International Society for Bipolar Disorder (ISBD), Pittsburgh, PA, USA
- 2011 Panel presentation “Glutamatergic modulation as a potential therapeutic target in mood disorders” at World Congress of Psychiatry (WPA), Buenos Aires, Argentina
- 2011 Panel presentation “Novel MRS approaches to study white matter abnormalities in schizophrenia” at International Congress on Schizophrenia Research (ICOSR), Colorado Springs, CO, USA
- 2011 Panel presentation “MRS approaches to glutamatergic abnormalities in schizophrenia” at ICOSR, Colorado Springs, CO, USA
- 2012 Panel presentation “Bioenergetic abnormalities in bipolar disorder” at the Annual Meeting of the ISBD, Istanbul, Turkey
- 2012 Invited talk “Postmortem studies in bipolar disorder” at Millenium Notes from Cappadocia meeting, Avanos, Turkey
- 2013 Invited talk “Neurobiology of Schizophrenia” at National Medical Students Science day, Bursa, Turkey
- 2013 Invited talk “Biomarkers in Schizophrenia Research” at annual meeting of Turkish Association of Psychopharmacology (TAP), Antalya, Turkey
- 2014 Invited talk “Neurobiologically based novel treatments for schizophrenia” at annual meeting of the Alberta Psychiatric Association, Banff, Alberta, Canada
- 2014 Invited talk “Psychiatric genetics – are we rowing upstream?” at annual meeting of TAP, Antalya, Turkey
- 2014 Invited talk “Novel treatments for schizophrenia” at Train-the-trainers satellite session to the annual meeting of Chinese Society of Psychiatry (CSP), XiAn, China
- 2014 Invited talk “Use of antipsychotics for insomnia” at Train-the-trainers satellite session to the annual meeting of Chinese Society of Psychiatry (CSP), XiAn, China
- 2014 Invited talk “The future of psychopharmacology” at the annual meeting of Chinese Society of Psychiatry (CSP), XiAn, China

- 2015 Invited talk “Care fragmentation and design of a randomized clinical trial to reduce cardiovascular complications and enhance care within mental health clinics” at the Twelfth Workshop on Costs and Assessment in Psychiatry – International Center for Mental Health Economics, Venice, Italy
- 2015 Panel speaker “Brain changes with cognitive training in bipolar disorder with psychosis” at the Annual Meeting of SOBP, Toronto, ON, Canada
- 2015 Panel chair for “Mood disorders: Neuroimaging” at the Annual Meeting of SOBP, Toronto, ON, Canada
- 2015 Panel speaker “In vivo stimulation induced bioenergetic abnormalities in bipolar disorder” at the Annual Meeting of the ISBD, Toronto, ON, Canada
- 2015 Invited speaker for Educational Session “Problems of psychiatric nosology and the RDoC framework” at the Annual Meeting of the World Congress of Psychiatric Genetics, Toronto, ON, Canada
- 2015 Panel speaker “In vivo studies of bioenergetic abnormalities in schizophrenia” at the Annual Meeting of the World Congress of Psychiatric Genetics, Toronto, ON, Canada
- 2016 Plenary Lecture “Metabolism, cognition, and behavior” at the 5th Global Symposium on Ketogenic Therapies, Banff, AL, Canada
- 2016 Invited speaker “Bioenergetic abnormalities in psychotic disorders: Implications for long-term outcomes” at the 5th Kraepelin Symposium at Ludwig-Maximilians University, Munich, Germany
- 2016 Plenary Lecture “New treatment development in schizophrenia: clinical perspectives” at the Annual Meeting of the Turkish Psychiatric Association, Antalya, Turkey
- 2016 Panel speaker “Neuroimaging approaches for clinical utility in schizophrenia and bipolar disorder” at the Annual Meeting of the Turkish Psychiatric Association, Antalya, Turkey
- 2017 Panel speaker “³¹P MRS Studies of bioenergetics in schizophrenia” at the Annual Meeting of the International Congress on Schizophrenia Research, San Diego, CA, USA
- 2017 Invited Keynote Speaker “³¹P MRS Studies of bioenergetics in schizophrenia” at the Annual Institute Days, Neuroscience Institute of Hacettepe University Medical School, Ankara, Turkey

- 2017 Plenary Speaker “Contribution of Neuroimaging to Clinical Psychiatry” at the Annual Meeting of the Turkish Association of Psychopharmacology, Antalya, Turkey
- 2017 Invited speaker “Research in Psychotic Disorders” at West China Hospital, Chengdu, China
- 2017 Invited speaker “Antipsychotic Medications” at the First Hospital of Hebei Medical University, Shijiazhuang, China
- 2018 Panel Speaker “Diffusion MRI studies in schizophrenia implicate glial cells” at the biannual meeting of the Schizophrenia International Research Society, Florence, Italy
- 2018 Plenary Speaker “Antiinflammatory treatments in schizophrenia and bipolar disorder” at the Annual Meeting of the Turkish Association of Psychopharmacology, Antalya, Turkey
- 2019 Panel Speaker “White matter abnormalities in schizophrenia” at the Annual Meeting of the Turkish Association of Psychopharmacology, Antalya, Turkey
- 2019 Fireside Chat leader “What do editors at top journals look for?”, at the Annual Meeting of the European College of Neuropsychopharmacology, Copenhagen, Denmark
- 2019 Invited Speaker “View from JAMA Psychiatry”, NORMENT Research Center, Oslo, Norway
- 2019 Invited Speaker “Careers in academic psychiatry”, Annual Meeting of the Turkish Psychiatric Association, Istanbul, Turkey
- 2020 Invited Speaker “Current diagnostic systems DSM/ICD” at International Workshop on Diagnosis with Utility, Amsterdam, Netherlands
- 2020 Grand Rounds “Bioenergetic abnormalities in psychosis: Finding the pathways”, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada (VIRTUAL)
- 2020 Friday Seminars “Bioenergetic abnormalities in psychotic disorders”, Orygen, Melbourne, Australia (VIRTUAL)
- 2020 Residency teaching seminar “Neuroimaging studies in psychotic disorders”, Ege University Medical School, Izmir, Turkey (VIRTUAL)
- 2020 Panel discussion “Effects of COVID-19 on psychiatry around the world” at the Annual Meeting of Turkish Psychiatric Society (VIRTUAL)

integrated into the model, with over half of all patients receiving care in the clinic also participating in studies.

2. Established the McLean PACT team, a community-based treatment program for high-utilizer patients with psychotic disorders. The team launched in 2017 and has enrolled over 30 patients since. The team consists of 5 staff members who provide service in the community, in patients' homes and anywhere else where assistance is needed.
3. Initiated a "biobanking" project in the clinical services of the Psychotic Disorders Division in 2006. This project involves regular clinical assessment data collection as well as blood samples for DNA from patients receiving care in our services. Over 2000 patients have participated in this project, and this effort has served as a model for other services within McLean.

Report of Education of Patients and Service to the Community

Activities

- | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2004 | Nationally syndicated "Doug Stephan's Good Day USA" radio program discussing Psychotic Disorders |
| 2005 | ABC's World News Tonight discussing Bipolar Disorder |
| 2008 | Consultant for ABC News Online Mental Health Resource "Bipolar Disorder" section |
| 2011 | Invited guest on "Radio Boston" program on local radio station WBUR discussing the "Voice Hearers' Network" |
| 2012 | Invited "Talkback" Speaker, Harvard University student theater production of Pulitzer-Price winning play "Next to Normal" |
| 2013 | Harvard University Conti-CBS program presentation to visiting High School teachers from Massachusetts on "Neurobiology of Schizophrenia and its treatment implications" |
| 2013 | Featured on the Pat Lawrence show on Belmont, MA local access television channel; topic "Recovery in mental illness" |
| 2014 | Featured in USA Today newspaper and Time magazine discussing Suicide |
| 2015 | Invited speaker at "Depression, Resilience, and Suicide", Museum of Science event; Boston, MA |
| 2016 | Invited commentator at screening of "Gabriel", a film about the experience of psychosis, Museum of Fine Art, Boston, MA |
| 2016 | Invited columnist for mass email communication on "Cannabis and psychosis" by National Alliance for Mental Illness |

- 2016 Invited panelist on “Synaptic Gap: 21st Century Brain Science meets Mental Health Treatment and Policy” at HUBWeek organized by Boston Globe/MGH/MIT, Boston, MA
- 2016 Featured on the Boston Globe front page on “Deconstructing Stigma Campaign by McLean Hospital”
- 2017 Featured on Vice Media special on “Cannabis and Psychosis”
- 2017 Invited speaker at event introducing PsychosisAware, a screening tool by Screening for Mental Health Inc. at the Museum of Science, Boston, MA
- 2017 “Ask the Doctor” discussant, NAMI Massachusetts Annual Convention, Taunton, MA
- 2017 Invited panelist on “PsychosisAware” webinar by Screening for Mental Health Inc.
- 2020 Interviewed on “In It Together” program on WGBH on the Coronavirus pandemic
- 2020 Interview with Oprah Winfrey for Oprah’s Book Club on the book “Hidden Valley Road” on the impact of schizophrenia on families
- 2020 Interview on “Schizoaffective disorder” with www.insider.com, a website informing the lay public about common health problems.
- 2021 Invited participant: “Innovation in Mood Disorders Research” webinar organized by Mindful Philanthropy
- 2021 Oral testimony before the MA Joint Committee on Financial Services on “S.646/H.1062 An Act for supportive care for serious mental illness”
- 2022 Featured speaker on “Schizophrenia Explained: Symptoms, Developments in Treatment, and More” Video on the Mass General Brigham YouTube channel

Report of Scholarship

Peer Reviewed Publications in print or other media

Research Investigations

1. Deutch AY, **Öngür D**, Duman RS (1995) Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus: a novel locus of antipsychotic drug action. *Neuroscience* **66**:337-346.

2. Black KJ, **Öngür D**, Perlmutter JS (1998) Putamen volume in idiopathic focal dystonia. *Neurology* **51**:819-824.
3. An X, Bandler R, **Öngür D**, Price JL (1998) Prefrontal cortical projections to longitudinal columns in the midbrain periaqueductal gray in macaque monkeys. *J. Comp. Neurol.* **401**:455-479.
4. **Öngür D**, An X, Price JL (1998) Prefrontal cortical projections to the hypothalamus in macaque monkeys. *J. Comp. Neurol.* **401**:480-505.
5. Drevets WC, **Öngür D**, Price JL (1998) Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders. *Mol. Psychiatry* **3**:220-226.
6. **Öngür D**, Drevets WC, Price JL (1998) Glial reduction in the subgenual prefrontal cortex in mood disorders. *Proc. Natl. Acad. Sci. USA* **95**:13290-13295.
7. Simpson JR, **Öngür D**, Akbudak E, Conturo TE, Ollinger JM, Snyder AZ, Gusnard DA, Raichle ME (2000) The emotional modulation of cognitive processing: an fMRI study. *J. Cogn. Neurosci.* **12 Suppl 2**:157-170.
8. Ferry AT, **Öngür D**, An X, Price JL (2000) Prefrontal cortical projections to the striatum in macaque monkeys: evidence for an organization related to prefrontal networks. *J. Comp. Neurol.* **425**:447-470.
9. Bowley MP, Drevets WC, **Öngür D**, Price JL (2002) Low glial numbers in the amygdala in Major Depressive Disorder. *Biol. Psychiatry* **52**:404-412.
10. **Öngür D**, Ferry AT, Price JL (2003) Architectonic analysis of the human orbital and medial prefrontal cortex. *J. Comp. Neurol.* **460**: 425-449.
11. **Öngür D**, Farabaugh A, Iosifescu DV, Perlis R, Fava M (2005) Tridimensional personality questionnaire factors in major depressive disorder: relationship to anxiety disorder comorbidity and age of onset. *Psychother. Psychosom.* **74**: 173-8
12. **Öngür D**, Goff DC (2005) Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status. *Schizophr. Res.* **75**: 349-62
13. **Öngür D**, Zalesak M, Weiss AP, Ditman T, Titone D, Heckers S (2005) Hippocampal activation during processing of previously seen visual stimulus pairs. *Psychiatry Res. Neuroimaging* **139**: 191-8
14. Farabaugh A, **Öngür D**, Fava M, Hamill SK, Burns AM, Alpert J (2005) Personality disorders and the tridimensional personality questionnaire factors in major depressive disorder. *J. Nerv. Ment. Dis.* **193**: 747-50

15. **Öngür D**, Cullen TJ, Wolf DH, Rohan M, Barreira P, Zalesak M, Heckers S (2006) The neural basis of relational memory deficits in schizophrenia. *Arch. Gen. Psychiatry* **63**: 356-65
16. Glick ID, Salzman C, Cohen BM, Klein DF, Moutier C, Nasrallah HA, **Öngür D**, Wang P, Zisook S (2007) Improving the pedagogy associated with the teaching of psychopharmacology. *Acad. Psychiatry* **31**: 211-7
17. Naydenov AV, MacDonald ML, **Öngür D**, Konradi C (2007) Differences in lymphocyte electron transport gene expression levels between subjects with bipolar disorder and normal controls in response to glucose deprivation stress. *Arch Gen Psychiatry* **64**: 555-64
18. **Öngür D**, Pohlman J, Dow AL, Eisch AJ, Edwin F, Heckers S, Cohen BM, Patel TB, Carlezon WA Jr (2007) Electroconvulsive seizures stimulate glial proliferation and reduce expression of Sprouty2 within the prefrontal cortex of rats. *Biol. Psychiatry* **62**: 505-12
19. Chen Y, Norton D, **Öngür D**, Heckers S (2007) Inefficient face detection in schizophrenia. *Schizophrenia Bull* **34**: 367-74
20. Yildiz A, Guleryuz S, Ankerst DP, **Öngür D**, Renshaw PF (2008) Protein kinase C inhibition in the treatment of mania: A double-blind, placebo-controlled trial of tamoxifen. *Arch Gen Psychiatry* **65**: 255-63
21. Abler B, Greenhouse I, **Öngür D**, Walter H, Heckers S (2008) Abnormal reward system activation in mania. *Neuropsychopharmacology* **33**: 2217-27
22. Chen Y, Norton D, **Öngür D** (2008) Altered center-surround motion inhibition in schizophrenia. *Biol Psychiatry* **64**: 74-7
23. Karmacharya R, England ML, **Öngür D** (2008) Delirious mania: clinical features and treatment response. *J Affect Disord* **109**: 312-6
24. Norton D, **Öngür D**, Stromeyer C 3rd, Chen Y (2008) Altered 'three-flash' illusion in response to two light pulses in schizophrenia. *Schizophr Res* **103**: 275-82
25. **Öngür D**, Jensen JE, Prescott AP, Stork CE, Lundy M, Cohen BM, Renshaw PF (2008) Abnormal glutamatergic neurotransmission and neuronal-glia interactions in acute mania. *Biol Psychiatry* **64**: 718-26
26. **Öngür D**, Lin L, Cohen BM (2009) Clinical characteristics influencing age at onset in psychotic disorders. *Compr Psychiatry* **50**: 13-9
27. Chen Y, Norton D, McBain R, **Öngür D**, Heckers S (2009) Visual and cognitive processing of face information in schizophrenia: Detection, discrimination and working memory. *Schizophr Res* **107**: 92-8
28. **Öngür D**, Prescott AP, Jensen JE, Cohen BM, Renshaw PF (2009) Creatine abnormalities in schizophrenia and bipolar disorder. *Psychiatry Res. Neuroimaging* **172**: 44-8

29. Jensen JE, Licata SC, **Ongür D**, Friedman SD, Prescott AP, Henry ME, Renshaw PF. (2009) Quantification of J-resolved proton spectra in two-dimensions with LCModel using GAMMA-simulated basis sets at 4 Tesla. *NMR Biomed.* 22:762-9.
30. Lewandowski KE, DePaola J, Camsari GB, Cohen BM, **Ongür D**. (2009) Tactile, olfactory, and gustatory hallucinations in psychotic disorders: a descriptive study. *Ann Acad Med Singapore.* 38:383-5.
31. Norton D, McBain R, Holt DJ, **Öngür D**, Chen Y (2009) Association of impaired facial affect recognition with basic facial and visual processing deficits in schizophrenia. *Biol Psychiatry* **65**: 1094-8
32. **Öngür D**, Prescott AP, Jensen JE, Rouse ED, Cohen BM, Renshaw PF, Olson DP (2009) T2 relaxation time abnormalities in bipolar disorder and schizophrenia. *Magn Reson Med* **63**: 1-8
33. Kaufman MJ, Prescott AP, **Öngür D**, Evins AE, Barros TL, Medeiros CL, Covell J, Wang L, Fava M, Renshaw PF (2009) Oral glycine administration increases brain glycine/creatine ratios in men: A proton magnetic resonance spectroscopy study. *Psychiatry Res* **173**: 143-9
34. Brennan BP, Hudson JI, Jensen JE, McCarthy J, Roberts JL, Prescott AP, Cohen BM, Pope HG Jr, Renshaw PF, **Öngür D** (2010). Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. *Neuropsychopharmacology* **35**: 834-46
35. **Öngür D**, Lundy M, Greenhouse I, Shinn AK, Menon V, Cohen BM, Renshaw PF (2010) Default mode network abnormalities in bipolar disorder and schizophrenia. *Psychiatry Res Neuroimaging* **183**: 59-68
36. Bechtholt-Gompf AJ, Walther HV, Adams MA, Carlezon WA Jr, **Öngür D**, Cohen BM (2010) Blockade of astrocytic glutamate uptake in rats induces signs of anhedonia without dysphoria and impaired spatial memory. *Neuropsychopharmacology* **35**: 2049-59
37. **Öngür D**, Prescott AP, McCarthy JM, Cohen BM, Renshaw PF (2010) Elevated gamma-aminobutyric acid levels in chronic schizophrenia. *Biol Psychiatry* **68**: 667-70
38. England ML, **Öngür D**, Konopaske GT, Karmacharya R (2011) Catatonia in Psychotic Patients: Clinical Features and Treatment Response. *J Neuropsych Clin Neurosci* **23**:223-6
39. Demirtas-Tatlidede A, Freitas C, Cromer JR, Safar L, **Öngür D**, Stone WS, Seidman LJ, Schmahmann JD, Pascual-Leone A (2010) Safety and proof of principle study of cerebellar vermal theta burst stimulation in refractory schizophrenia. *Schizophrenia Res.* **124**: 91-100
40. Chen Y, McBain R, Norton D, **Öngür D** (2011) Schizophrenia patients show augmented spatial frame illusion for visual and visuomotor tasks. *Neuroscience* **172**: 419-26
41. Bracken B, Jensen JE, Prescott AP, Cohen BM, Renshaw PF, **Öngür D** (2011) Brain metabolite concentrations across cortical regions in healthy adults. *Brain Res.* **1369**: 89-94

42. Bechtholt-Gompf AJ, Smith KL, John CS, Kang HH, Carlezon WA Jr, Cohen BM, **Öngür D** (2011) CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy. *Psychopharmacology* **215**: 689-95
43. **Ongür D**, Haddad S, Prescott AP, Jensen JE, Siburian R, Cohen BM, Renshaw PF, Smoller JW (2011) Relationship Between Genetic Variation in the Glutaminase Gene GLS1 and Brain Glutamine/Glutamate Ratio Measured In Vivo. *Biol. Psychiatry* **70**:169-74
44. Chai XJ, Whitfield-Gabrieli S, Shinn AK, Gabrieli JDE, Castañón AN, McCarthy JM, Cohen BM, **Öngür D** (2011) Abnormal medial prefrontal cortex resting-state connectivity in bipolar disorder and schizophrenia. *Neuropsychopharmacology*, 36(10):2009-17.
45. Teter CJ, Falone AE, Bakaian AM, Tu C, **Öngür D**, Weiss RD (2011) Medication adherence and attitudes in patients with bipolar disorder and current versus past substance use disorder. *Psychiatry Res.* 190(2-3):253-8.
46. Chai XJ, Castañón AN, **Öngür D**, Whitfield-Gabrieli S (2011) Anticorrelations in resting state networks without global signal regression. *Neuroimage.* 59(2):1420-8.
47. Chen Y, Cataldo A, Norton DJ, **Öngür D** (2011) Distinct facial processing in schizophrenia and schizoaffective disorders. *Schizophr Res.* 134(1):95-100.
48. Norton DJ, McBain RK, **Öngür D**, Chen Y (2011) Perceptual training strongly improves visual motion perception in schizophrenia. *Brain Cogn.* 77(2):248-56.
49. Lewandowski KE, Cohen BM, Keshavan MS, **Öngür D** (2011) Relationship of neurocognitive deficits to diagnosis and symptoms across affective and non-affective psychoses. *Schizophr Res.* 133(1-3):212-7
50. Shinn AK, Pfaff D, Young S, Lewandowski KE, Cohen BM, **Ongür D** (2011) Auditory hallucinations in a cross-diagnostic sample of psychotic disorder patients: a descriptive, cross-sectional study. *Compr Psychiatry* 53:718-26.
51. Yüksel C, McCarthy JM, Shinn AK, Pfaff DL, Baker JT, Heckers S, Renshaw PF, **Ongür D** (2012) Gray matter volume in schizophrenia and bipolar disorder with psychotic features. *Schizophr Res.* 138:177-82.
52. Du F, Cooper A, Cohen BM, Renshaw PF, **Ongür D** (2012) Water and metabolite transverse T2 relaxation time abnormalities in the white matter in schizophrenia. *Schizophr Res.* 137:241-5.
53. John CS, Smith KL, Van't Veer A, Gompf HS, Carlezon WA Jr, Cohen BM, **Ongür D**, Bechtholt-Gompf AJ (2012) Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia. *Neuropsychopharmacology* 37(11):2467-75.
54. Du F, Cooper A, Lukas SE, Cohen BM, **Ongür D** (2012) Creatine kinase and ATP synthase reaction rates in human frontal lobe measured by ³¹P magnetization transfer spectroscopy at 4T. *Magn Reson Imaging.* 31:102-8.

55. Young S, Pfaff D, Lewandowski KE, Ravichandran C, Cohen BM, **Ongür D** (2012) Anxiety Disorder Comorbidity in Bipolar Disorder, Schizophrenia and Schizoaffective Disorder. *Psychopathology*. 46:176-85.
56. Brady RO Jr, Cooper A, Jensen JE, Tandon N, Cohen B, Renshaw P, Keshavan M, **Ongür D** (2012) A longitudinal pilot proton MRS investigation of the manic and euthymic states of bipolar disorder. *Transl Psychiatry*. 2:e160.
57. Centorrino F, Masters GA, Talamo A, Baldessarini RJ, **Ongür D** (2012) Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. *Hum Psychopharmacol*. 27(5):521-6
58. Shinn AK, Baker JT, Cohen BM, **Ongür D** (2012) Functional connectivity of left Heschl's gyrus in vulnerability to auditory hallucinations in schizophrenia. *Schizophr Res*. 143:260-8.
59. Wong Z, **Ongür D**, Cohen BM, Ravichandran C, Noam G, Murphy B (2013) Command hallucinations and clinical characteristics of suicidality in patients with psychotic spectrum disorders. *Compr Psychiatry* 54:611-7.
60. Shinn AK, Heckers S, **Ongür D** (2013) The special treatment of first rank auditory hallucinations and bizarre delusions in the diagnosis of schizophrenia. *Schizophr Res*. 146:17-21.
61. Fan X, Liu E, Freudenreich O, Copeland P, Hayden D, Ghebremichael M, Cohen B, **Öngür D**, Goff DC, Henderson DC (2013) No effect of adjunctive, repeated-dose intranasal insulin treatment on psychopathology and cognition in patients with schizophrenia. *J Clin Psychopharmacol*. 33(2):226-30
62. Du F, Cooper AJ, Thida T, Shinn AK, Cohen BM, **Ongür D** (2013) Myelin and Axon Abnormalities in Schizophrenia Measured with Magnetic Resonance Imaging Techniques. *Biol Psychiatry* 76:451-7.
63. Brady RO Jr, McCarthy JM, Prescott AP, Jensen JE, Cooper AJ, Cohen BM, Renshaw PF, **Ongür D** (2013) Brain gamma-aminobutyric acid (GABA) abnormalities in bipolar disorder. *Bipolar Disord*. 15:434-9.
64. Valenzuela M, Bartes-Faz D, Beg F, Fornito A, Merlo-Pich E, Müller U, **Öngür D**, Toga AW, Yücel M (2011) Neuroimaging as Endpoints in Clinical Trials: Perspective from the first Provence Workshop. *Mol Psychiatry* 16:1064-6.
65. Rosmarin DH, Bigda-Peyton JS, **Öngür D**, Pargament KI, Björgvinsson T (2013) Religious coping among psychotic patients: Relevance to suicidality and treatment outcomes. *Psychiatry Res*. 210:182-7.
66. Lewandowski KE, Cohen BM, Keshavan MS, Sperry SH, **Ongür D** (2013) Neuropsychological functioning predicts community outcomes in affective and non-affective psychoses: A 6-month follow-up. *Schizophr Res*. 148:34-7.

67. Kim J, Norton D, McBain R, **Öngür D**, Chen Y (2013) Deficient biological motion perception in schizophrenia: results from a motion noise paradigm. *Front Psychol.* 4:391.
68. Du F, Cooper AJ, Thida T, Sehovic S, Lukas SE, Cohen BM, Zhang X, **Öngür D** (2014) In Vivo Evidence for Cerebral Bioenergetic Abnormalities in Schizophrenia Measured Using ³¹P Magnetization Transfer Spectroscopy. *JAMA Psychiatry* 71:19-27.
69. Baker JT, Holmes AJ, Masters GA, Yeo BT, Krienen F, Buckner RL, **Öngür D**. (2014) Disruption of cortical association networks in schizophrenia and psychotic bipolar disorder. *JAMA Psychiatry.* 71(2):109-18.
70. Hall MH, Levy DL, Salisbury DF, Haddad S, Gallagher P, Lohan M, Cohen B, **Öngür D**, Smoller JW. (2014) Neurophysiologic effect of GWAS derived schizophrenia and bipolar risk variants. *Am J Med Genet B Neuropsychiatr Genet.* 165(1):9-18.
71. Masters GA, Baldessarini RJ, **Öngür D**, Centorrino F. (2014) Factors associated with length of psychiatric hospitalization. *Compr Psychiatry.* 55(3):681-7.
72. Smoller JW, Gallagher PJ, Duncan LE, McGrath LM, Haddad SA, Holmes AJ, Wolf AB, Hilker S, Block SR, Weill S, Young S, Choi EY, Rosenbaum JF, Biederman J, Faraone SV, Roffman JL, Manfro GG, Blaya C, Hirshfeld-Becker DR, Stein MB, Van Ameringen M, Tolin DF, Otto MW, Pollack MH, Simon NM, Buckner RL, **Öngür D**, Cohen BM. (2014) The Human Ortholog of Acid-Sensing Ion Channel Gene ASIC1a Is Associated with Panic Disorder and Amygdala Structure and Function. *Biol Psychiatry.* 76:902-10.
73. Duncan LE, Holmans PA, Lee PH, O'Dushlaine CT, Kirby AW, Smoller JW, **Öngür D**, Cohen BM. (2014) Pathway analyses implicate glial cells in schizophrenia. *PLoS One.* 9(2):e89441.
74. Smith KL, John CS, Sypek EI, **Öngür D**, Cohen BM, Barry SM, Bechtholt AJ. (2014) Exploring the Role of Central Astrocytic Glutamate Uptake in Ethanol Reward in Mice. *Alcohol Clin Exp Res.* 38:1307-14.
75. Lewandowski KE, Sperry SH, Cohen BM, **Öngür D** (2014) Cognitive variability in psychotic disorders: a cross-diagnostic cluster analysis. *Psychol Med.* 44:3239-48.
76. Martin EA, Cohen BM, **Öngür D**, Lewandowski KL (2014) Social functioning and age across affective and non-affective psychoses. *J Nerv Ment Dis.* 203:37-42.
77. Yoshimizu T, Pan JQ, Mungenast AE, Madison JM, Su S, Ketterman J, **Öngür D**, McPhie D, Cohen B, Perlis R, Tsai LH (2014) Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons. *Mol Psychiatry.* 20:162-9.

78. Lewandowski KE, **Öngür D**, Sperry SH, Cohen BM, Sehovic S, Goldbach JR, Du F (2014) Myelin versus Axon Abnormalities in White Matter in Bipolar Disorder. *Neuropsychopharmacology*. 40:1243-9.
79. Atagün MI, Sikoğlu EM, Can SS, Karakaş-Uğurlu G, Ulusoy-Kaymak S, Cayköylü A, Algin O, Phillips ML, Moore CM, **Öngür D** (2015) Investigation of Heschl's gyrus and planum temporale in patients with schizophrenia and bipolar disorder: A proton magnetic resonance spectroscopy study. *Schizophr Res*. 161:202-9.
80. John CS, Sypek EI, Carlezon WA Jr, Cohen BM, **Öngür D**, Bechtholt AJ (2015) Blockade of the GLT-1 Transporter in the Central Nucleus of the Amygdala Induces Both Anxiety and Depressive-Like Symptoms. *Neuropsychopharmacology*. 40:1700-8.
81. Macias C, Panch T, Hicks YM, Scolnick JS, Weene DL, **Öngür D**, Cohen BM (2015) Using Smartphone Apps to Promote Psychiatric and Physical Well-Being. *Psychiatr Q*. 86:505-19.
82. Hall MH, Jensen JE, Du F, Smoller JW, O'Connor L, Spencer KM, **Öngür D** (2015) Frontal P3 event-related potential is related to brain glutamine/glutamate ratio measured in vivo. *Neuroimage*. 111:186-191.
83. Hall MH, Chen CY, Cohen BM, Spencer KM, Levy DL, **Öngür D**, Smoller JW (2015) Genomewide association analyses of electrophysiological endophenotypes for schizophrenia and psychotic bipolar disorders: A preliminary report. *Am J Med Genet B Neuropsychiatr Genet*. 168(3):151-61.
84. Chyzyk D, Graña M, **Öngür D**, Shinn AK (2015) Discrimination of Schizophrenia Auditory Hallucinators by Machine Learning of Resting-State Functional MRI. *Int J Neural Syst*. 25:1550007.
85. Yuksel C, Du F, Ravichandran C, Goldbach JR, Thida T, Lin P, Dora B, Gelda J, O'Connor L, Sehovic S, Gruber S, **Öngür D**, Cohen BM (2015) Abnormal high-energy phosphate molecule metabolism during regional brain activation in patients with bipolar disorder. *Mol Psychiatry*. 20:1079-84.
86. Dow AL, Lin TV, Chartoff EH, Potter D, McPhie DL, Van't Veer AV, Knoll AT, Lee KN, Neve RL, Patel TB, **Öngür D**, Cohen BM, Carlezon WA Jr. (2015) Sprouty2 in the dorsal hippocampus regulates neurogenesis and stress responsiveness in rats. *PLoS One*. 10(3):e0120693.
87. Castro VM, Minnier J, Murphy SN, Kohane I, Churchill SE, Gainer V, Cai T, Hoffnagle AG, Dai Y, Block S, Weill SR, Nadal-Vicens M, Pollastri AR, Rosenquist JN, Goryachev S, **Öngür D**, Sklar P, Perlis RH, Smoller JW; International Cohort Collection for Bipolar Disorder Consortium (2015) Validation of electronic health record phenotyping of bipolar disorder cases and controls. *Am J Psychiatry*. 172(4):363-72.

88. Shinn AK, Baker JT, Lewandowski KE, **Öngür D**, Cohen BM (2015) Aberrant cerebellar connectivity in motor and association networks in schizophrenia. *Front Hum Neurosci.* 9:134.
89. Sperry SH, O'Connor LK, **Öngür D**, Cohen BM, Keshavan MS, Lewandowski KE (2015) Measuring cognition in bipolar disorder with psychosis using the MATRICS consensus cognitive battery. *J Int Neuropsychol Soc.* 8:1-5.
90. Maher S, Ekstrom T, Holt D, **Öngür D**, Chen Y (2015) The core brain region for face processing in schizophrenia lacks face selectivity. *Schizophr Bull.* (Epub 2015 Oct 9) pii: sbv140
91. Zhang B, Lin P, Shi H, **Öngür D**, Auerbach RP, Wang X, Yao S, Wang X (2015) Mapping anhedonia-specific dysfunction in a transdiagnostic approach: an ALE meta-analysis. *Brain Imaging Behav.* (Epub 2015 Oct 20)
92. Macias C, Gold PB, **Öngür D**, Cohen BM, Panch T (2015) Are Single-Item Global Ratings Useful for Assessing Health Status? *J Clin Psychol Med Settings.* (Epub 2015 Oct 22)
93. Moran LV, Masters GA, Pingali S, Cohen BM, Liebson E, Rajarethinam RP, **Öngür D**. (2015) Prescription stimulant use is associated with earlier onset of psychosis. *J Psychiatr Res.* 71:41-7.
94. Shinn AK, Bolton KW, Karmacharya R, Lewandowski KE, Yuksel C, Baker JT, Chouinard VA, Pingali SM, Bye H, Cederbaum K, **Öngür D**. (2015) McLean OnTrack: a transdiagnostic program for early intervention in first-episode psychosis. *Early Interv Psychiatry.* (Epub 2015 Nov 29)
95. Ekstrom T, Maher S, Shinn A, **Öngür D**, Chen Y. (2016) Face identity discrimination in schizophrenia: Impairments to faces with high exposure in society. *Schizophr Res.* (Epub 2016 Jan 15)
96. Chouinard VA, Pingali SM, Chouinard G, Henderson DC, Mallya SG, Cypess AM, Cohen BM, **Öngür D**. (2016) Factors associated with overweight and obesity in schizophrenia, schizoaffective and bipolar disorders. *Psychiatry Res.* (Epub 2016 Jan 14)
97. Lewandowski KE, Sperry SH, **Öngür D**, Cohen BM, Norris LA, Keshavan MS. (2016) Cognitive remediation versus active computer control in bipolar disorder with psychosis: study protocol for a randomized controlled trial. *Trials.* (Epub 2016 Mar 12)
98. Brady RO Jr, Masters GA, Mathew IT, Margolis A, Cohen BM, **Öngür D**, Keshavan M. (2016) State dependent cortico-amygdala circuit dysfunction in bipolar disorder. *J Affect Disord.* (Epub 2016 Apr 28)

99. Yildiz A, Aydin B, Gokmen N, Yurt A, Cohen BM, Keskinoglu P, **Öngür D**, Renshaw PF (2016) Antimanic treatment with tamoxifen affects brain chemistry: double-blind placebo-controlled proton magnetic resonance spectroscopy study. *Biol Psych CNNI*. 1:125-32.
100. Lewandowski KE, Whitton AE, Pizzagalli DA, Norris LA, **Öngür D**, Hall MH. (2016) Reward Learning, Neurocognition, Social Cognition, and Symptomatology in Psychosis. *Front Psychiatry*. 7:100. eCollection 2016.
101. Zhou J, Xiang YT, Li Q, Zhu X, Li W, Ungvari GS, Ng CH, **Öngür D**, Wang X. (2016) Gender differences in attitudes towards antipsychotic medications in patients with schizophrenia. *Psychiatry Res*. 245:276-281.
102. Huang JH, Berkovitch SS, Iaconelli J, Watmuff B, Park H, Chattopadhyay S, McPhie D, **Öngür D**, Cohen BM, Clish CB, Karmacharya R (2016) Perturbational Profiling of Metabolites in Patient Fibroblasts Implicates α -Aminoadipate as a Potential Biomarker for Bipolar Disorder. *Mol Neuropsychiatry*. 2:97-106.
103. Kim SY, Cohen BM, Chen X, Lukas SE, Shinn AK, Yuksel AC, Li T, Du F, **Öngür D** (2016) Redox Dysregulation in Schizophrenia Revealed by in vivo NAD⁺/NADH Measurement. *Schizophr Bull*. (Epub 2016 Sep 24). PMID:27665001
104. Brady RO Jr, Tandon N, Masters GA, Margolis A, Cohen BM, Keshavan M, **Öngür D**. (2016) Differential brain network activity across mood states in bipolar disorder. *J Affect Disord*. 207:367-376. PMID: 27744225
105. Lee PH, Baker JT, Holmes AJ, Jahanshad N, Ge T, Jung JY, Cruz Y, Manoach DS, Hibar DP, Faskowitz J, McMahon KL, de Zubicaray GI, Martin NH, Wright MJ, **Öngür D**, Buckner R, Roffman J, Thompson PM, Smoller JW (2016) Partitioning heritability analysis reveals a shared genetic basis of brain anatomy and schizophrenia. *Mol Psychiatry*. (Epub 2016 Oct 11). PMID: 27725656
106. Berghorst LH, Kumar P, Greve DN, Deckersbach T, **Öngür D**, Dutra SJ, Pizzagalli DA. (2016) Stress and reward processing in bipolar disorder: a functional magnetic resonance imaging study. *Bipolar Disord*. 18(7):602-611. PMID: 27870507
107. Huang JH, Park H, Iaconelli J, Berkovitch SS, Watmuff B, McPhie D, **Öngür D**, Cohen BM, Clish CB, Karmacharya R (2017) Unbiased Metabolite Profiling of Schizophrenia Fibroblasts under Stressful Perturbations Reveals Dysregulation of Plasmalogens and Phosphatidylcholines. *J Proteome Res*. 16(2):481-493. PMID: 28152600
108. Atagün Mİ, Şıkoğlu EM, Soykan Ç, Serdar Süleyman C, Ulusoy-Kaymak S, Çayköylü A, Algın O, Phillips ML, **Öngür D**, Moore CM (2017) Perisylvian GABA levels in schizophrenia and bipolar disorder. *Neurosci Lett*. 637:70-74. PMID: 27890741

109. Gruber SA, Dahlgren MK, Sagar KA, Gonenc A, Norris L, Cohen BM, **Öngür D**, Lewandowski KE. (2017) Decreased Cingulate Cortex activation during cognitive control processing in bipolar disorder. *J Affect Disord.* 7;213:86-95. PMID: 28199893
110. Lee PH, Baker JT, Holmes AJ, Jahanshad N, Ge T, Jung JY, Cruz Y, Manoach DS, Hibar DP, Faskowitz J, McMahon KL, de Zubicaray GI, Martin NH, Wright MJ, **Öngür D**, Buckner R, Roffman J, Thompson PM, Smoller JW. (2017) Partitioning heritability analysis reveals a shared genetic basis of brain anatomy and schizophrenia. *Mol Psychiatry.* (Epub 2017 Feb 21). PMID: 28220043
111. Van Rheenen TE, Lewandowski KE, Tan EJ, Ospina LH, **Ongur D**, Neill E, Gurvich C, Pantelis C, Malhotra AK, Rossell SL, Burdick KE. (2017) Characterizing cognitive heterogeneity on the schizophrenia-bipolar disorder spectrum. *Psychol Med.* (Epub 2017 Feb 28). PMID: 28241891
112. Chouinard VA, Kim SY, Valeri L, Yuksel C, Ryan KP, Chouinard G, Cohen BM, Du F, **Öngür D**. (2017) Brain bioenergetics and redox state measured by 31P magnetic resonance spectroscopy in unaffected siblings of patients with psychotic disorders. *Schizophr Res.* (Epub 2017 Mar 1). PMID: 28258794
113. Nickerson LD, Smith SM, **Öngür D**, Beckmann CF. (2017) Using Dual Regression to Investigate Network Shape and Amplitude in Functional Connectivity Analyses. *Front Neurosci.* 11:115. doi:10.3389/fnins.2017.00115. eCollection 2017. PMID: 28348512
114. Brady RO Jr, Margolis A, Masters GA, Keshavan M, **Öngür D**. (2017) Bipolar mood state reflected in cortico-amygdala resting state connectivity: A cohort and longitudinal study. *J Affect Disord.* 217:205-209. PMID: 28415008
115. Ravichandran C, Shinn AK, **Öngür D**, Perlis RH, Cohen B. (2017) Frequency of non-right-handedness in bipolar disorder and schizophrenia. *Psychiatry Res.* 253:267-269. PMID: 28411573
116. Kim SY, Chen W, **Öngür D**, Du F. (2017) Rapid and simultaneous measurement of phosphorus metabolite pool size ratio and reaction kinetics of enzymes in vivo. *J Magn Reson Imaging.* (Epub 2017 May 8). PMID: 28480619
117. Du F, Yuksel C, Chouinard VA, Huynh P, Ryan K, Cohen BM, **Öngür D**. (2017) Abnormalities in High-Energy Phosphate Metabolism in First-Episode Bipolar Disorder Measured Using 31P-Magnetic Resonance Spectroscopy. *Biol Psychiatry.* (Epub 2017 Apr 7). PMID: 28527566

118. Shinn AK, Roh YS, Ravichandran CT, Baker JT, **Öngür D**, Cohen BM. (2017) Aberrant cerebellar connectivity in bipolar disorder with psychosis. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2(5):438-448. PMID: 28730183
119. Lewandowski KE, Sperry SH, Cohen BM, Norris LA, Fitzmaurice GM, **Öngür D**, Keshavan MS. (2017) Treatment to Enhance Cognition in Bipolar Disorder (TREC-BD): Efficacy of a Randomized Controlled Trial of Cognitive Remediation Versus Active Control. *J Clin Psychiatry*. (Epub 2017 Oct 17). PMID: 29045770
120. Lewandowski KE, Baker JT, McCarthy JM, Norris LA, **Öngür D**. (2017) Reproducibility of Cognitive Profiles in Psychosis Using Cluster Analysis. *J Int Neuropsychol Soc*. (Epub 2017 Oct 18) PMID: 29041995
121. Kim SY, Kaufman MJ, Cohen BM, Jensen JE, Coyle JT, Du F, **Öngür D**. (2017) In Vivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Time-Averaged Proton Magnetic Resonance Spectroscopy at 4T. *Biol Psychiatry*. (Epub 2017 Sep 7). PMID: 29031411
122. Baytunca B, Kalyoncu T, Ozel I, Erermiş S, Kayahan B, **Öngür D**. (2017) Early Onset Schizophrenia Associated With Obsessive-Compulsive Disorder: Clinical Features and Correlates. *Clin Neuropharmacol*. (Epub 2017 Oct 2). PMID: 28976410
123. Moran LV, Stoeckel LE, Wang K, Caine CE, Villafuerte R, Calderon V, Baker JT, **Öngür D**, Janes AC, Pizzagalli DA, Evins AE. (2017) Nicotine Increases Activation to Anticipatory Valence Cues In Anterior Insula and Striatum. *Nicotine Tob Res*. (Epub 2017 Sep 25). PMID: 29059451
124. Moran LV, Stoeckel LE, Wang K, Caine CE, Villafuerte R, Calderon V, Baker JT, **Öngür D**, Janes AC, Evins AE, Pizzagalli DA. (2017) Nicotine-induced activation of caudate and anterior cingulate cortex in response to errors in schizophrenia *Psychopharmacology (Berl)*. (Epub 2017 Nov 27). PMID: 29181816
125. Moran LV, Betts JM, **Öngür D**, Janes AC. (2017) Neural Responses to Smoking Cues in Schizophrenia. *Schizophr Bull*. (Epub 2017 Jul 4). PMID: 29106683
126. Lin P, Wang X, Zhang B, Kirkpatrick B, **Öngür D**, Levitt JJ, Jovicich J, Yao S, Wang X (2017) Functional dysconnectivity of the limbic loop of frontostriatal circuits in first-episode, treatment-naive schizophrenia. *Hum Brain Mapp*. (Epub 2017 Nov 2). PMID: 29094787

127. Yuksel C, Yilmaz S, Nesbit A, Carkaxhiu G, Ravichandran C, Salvatore P, Pingali S, Cohen B, **Öngür D** (2018) Demographic and clinical characteristics associated with a history of bizarre delusions in a cross-diagnostic sample of individuals with psychotic disorders. *Asian J Psychiatr.* (Epub 2018 Feb 9);31:82-85. PMID: 29453145
128. Chouinard VA, Henderson DC, Dalla Man C, Valeri L, Gray BE, Ryan KP, Cypess AM, Cobelli C, Cohen BM, **Öngür D.** (2018) Impaired insulin signaling in unaffected siblings and patients with first-episode psychosis. *Mol Psychiatry.* (Epub 2018 Mar 9) PMID: 29523870
129. Reinen JM, Chén OY, Hutchison RM, Yeo BTT, Anderson KM, Sabuncu MR, **Öngür D,** Roffman JL, Smoller JW, Baker JT, Holmes AJ. (2018) The human cortex possesses a reconfigurable dynamic network architecture that is disrupted in psychosis. *Nat Commun.* (Epub 2018 Mar 20);9(1):1157. PMID: 29559638
130. Chen X, Fan X, Hu Y, Zuo C, Whitfield-Gabrieli S, Holt D, Gong Q, Yang Y, Pizzagalli DA, Du F, **Öngür D.** (2018) Regional GABA Concentrations Modulate Inter-network Resting-state Functional Connectivity. *Cereb Cortex.* (Epub 2018 Mar 28) PMID: 29608677
131. Atagün Mİ, Şikoğlu EM, Can SS, Uğurlu GK, Kaymak SU, Çayköylü A, Algin O, Phillips ML, Moore CM, **Öngür D.** (2018) Neurochemical differences between bipolar disorder type I and II in superior temporal cortices: A proton magnetic resonance spectroscopy study. *J Affect Disord.* (Epub 2018 Aug 1); 235:15-19 PMID: 29631202
132. Lin YF, Chen CY, **Öngür D,** Betensky R, Smoller JW, Blacker D, Hall MH. (2018) Polygenic pleiotropy and potential causal relationships between educational attainment, neurobiological profile, and positive psychotic symptoms. *Transl Psychiatry.* (Epub 2018 May 16); 8(1):97. PMID: 29765027
133. Zhou TH, Mueller NE, Spencer KM, Mallya SG, Lewandowski KE, Norris LA, Levy DL, Cohen BM, **Öngür D,** Hall MH. (2018) Auditory steady state response deficits are associated with symptom severity and poor functioning in patients with psychotic disorder. *Schizophr Res.* (Epub 2018 May 25). PMID: 29807805
134. Yapici Eser H, Kacar AS, Kilciksiz CM, Yalçınay-Inan M, **Öngür D.** (2018) Prevalence and Associated Features of Anxiety Disorder Comorbidity in Bipolar Disorder: A Meta-Analysis and Meta-Regression Study. *Front Psychiatry.* (Epub 2018 Jun 27). PMID: 29997527

135. Lewandowski KE, McCarthy JM, **Öngür D**, Norris LA, Liu GZ, Juelich RJ, Baker JT. (2018) Functional connectivity in distinct cognitive subtypes in psychosis. *Schizophr Res.* (Epub 2018 Aug 17). PMID: 30126818
136. Mueller NE, Panch T, Macias C, Cohen BM, **Öngür D**, Baker JT. (2018) Using Smartphone Apps to Promote Psychiatric Rehabilitation in a Peer-Led Community Support Program: Pilot Study. *JMIR Ment Health.* 5(3):e10092. PMID: 30111526
137. Türközer HB, Hasoğlu T, Chen Y, Norris LA, Brown M, Delaney-Busch N, Kale EH, Pamir Z, Boyacı H, Kuperberg G, Lewandowski KE, Topçuoğlu V, **Öngür D**. (2018) Integrated assessment of visual perception abnormalities in psychotic disorders and relationship with clinical characteristics. *Psychol Med.* (Epub 2018 Sep 4). PMID: 30178729
138. McPhie DL, Nehme R, Ravichandran C, Babb SM, Ghosh SD, Staskus A, Kalinowski A, Kaur R, Douvaras P, Du F, **Öngür D**, Fossati V, Eggan K, Cohen BM. (2018) Oligodendrocyte differentiation of induced pluripotent stem cells derived from subjects with schizophrenias implicate abnormalities in development. *Transl Psychiatry.* (Epub 2018 Oct 23). PMID: 30352993
139. Lee I, Nielsen K, Nawaz U, Hall MH, **Öngür D**, Keshavan M, Brady R Jr. (2018) Diverse pathophysiological processes converge on network disruption in mania. *J Affect Disord.* 244:115-123. PMID: 30340100
140. Wang D, Li M, Wang M, Schoeppe F, Ren J, Chen H, **Öngür D**, Baker JT, Liu H. (2018) Individual-specific functional connectivity markers track dimensional and categorical features of psychotic illness. *Mol Psychiatry.* (Epub 2018 Nov 15). PMID: 30443042
141. Shinn AK, Yuksel C, Masters G, Pfaff D, Wamsley E, Djonlagic I, **Öngür D**, Manoach DS, Stickgold R. (2019) Procedural memory consolidation after a night of sleep in bipolar disorder with psychotic features. *Schizophr Res.* (Epub 2019 Jan 3). PMID: 30611654
142. Brady RO Jr, Gonsalvez I, Lee I, **Öngür D**, Seidman LJ, Schmahmann JD, Eack SM, Keshavan MS, Pascual-Leone A, Halko MA. (2019) Cerebellar-Prefrontal Network Connectivity and Negative Symptoms in Schizophrenia. *Am J Psychiatry.* (Epub 2019 Jan 30). PMID: 30696271
143. Shao Z, Noh H, Bin Kim W, Ni P, Nguyen C, Cote SE, Noyes E, Zhao J, Parsons T, Park JM, Zheng K, Park JJ, Coyle JT, Weinberger DR, Straub RE, Berman KF, Apud J, **Öngür D**, Cohen BM, McPhie DL, Rapoport JL, Perlis RH, Lanz TA, Xi HS, Yin C,

- Huang W, Hirayama T, Fukuda E, Yagi T, Ghosh S, Eggen KC, Kim HY, Eisenberg LM, Moghadam AA, Stanton PK, Cho JH, Chung S. (2019) Dysregulated protocadherin-pathway activity as an intrinsic defect in induced pluripotent stem cell-derived cortical interneurons from subjects with schizophrenia. *Nat Neurosci.* 22(2):229-242. PMID: 30664768
144. Chouinard VA, Shinn AK, Valeri L, Chouinard PA, Gardner ME, Asan AE, Cohen BM, **Öngür D**. (2019) Visual hallucinations associated with multimodal hallucinations, suicide attempts and morbidity of illness in psychotic disorders. *Schizophr Res.* (Epub 2019 Mar 3). PMID: 30842029
145. Hall MH, Holton KM, **Öngür D**, Montrose D, Keshavan MS. (2019) Longitudinal trajectory of early functional recovery in patients with first episode psychosis. *Schizophr Res.* (Epub 2019 Feb 27). PMID:30826261
146. Murphy M, **Öngür D**. (2019) Decreased peak alpha frequency and impaired visual evoked potentials in first episode psychosis. *Neuroimage Clin.* (Epub 2019 Feb 21) PMID: 30825710
147. Yang ZY, Zhang RT, Li Y, Wang Y, Wang YM, Wang SK, **Öngür D**, Cheung EFC, Chan RCK. (2019) Functional connectivity of the default mode network is associated with prolepsis in schizophrenia patients and individuals with social anhedonia. *Prog Neuropsychopharmacol Biol Psychiatry.* 92:412-420. PMID: 30822447
148. Chen X, Tamang SM, Du F, **Öngür D**. (2019) Glutamate diffusion in the rat brain in vivo under light and deep anesthesia conditions. *Magn Reson Med.* (Epub 2019 Mar 12). PMID: 30860289
149. Ling G, Lee I, Guimond S, Lutz O, Tandon N, Nawaz U, **Öngür D**, Eack S, E Lewandowski K, Keshavan M, Brady R Jr. (2019) Individual variation in brain network topology is linked to emotional intelligence. *Neuroimage.* (Epub 2019 Apr 1) PMID: 30630078
150. Moran LV, **Öngür D**, Hsu J, Castro VM, Perlis RH, Schneeweiss S. (2019) Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. *N Engl J Med.* 380(12):1128-1138. PMID: 30893533
151. Baker JT, Dillon DG, Patrick LM, Roffman JL, Brady RO Jr, Pizzagalli DA, **Öngür D**, Holmes AJ. (2019) Functional connectomics of affective and psychotic pathology. *Proc Natl Acad Sci U S A.* 116(18):9050-9059. PMID: 30988201

152. Lewandowski KE, Du F, Fan X, Chen X, Huynh P, **Öngür D**. (2019) Role of glia in prefrontal white matter abnormalities in first episode psychosis or mania detected by diffusion tensor spectroscopy. *Schizophr Res*. 209:64-71. PMID: 31101514
153. Zhang B, Lin P, Wang X, **Öngür D**, Ji X, Situ W, Yao S, Wang X. (2019) Altered Functional Connectivity of Striatum Based on the Integrated Connectivity Model in First-Episode Schizophrenia. *Front Psychiatry*. 10:756. PMID: 31681050
154. Yang ZY, Wang SK, Li Y, Wang Y, Wang YM, Zhou HY, Cai XL, Cheung EFC, Shum DHK, **Öngür D**, Chan RCK. (2019) Neural correlates of prospection impairments in schizophrenia: Evidence from voxel-based morphometry analysis. *Psychiatry Res Neuroimaging*. (Epub 2019 Oct 8). PMID: 31629132
155. Murphy M, Stickgold R, **Öngür D**. (2019) Electroencephalogram Microstate Abnormalities in Early-Course Psychosis. *Biol Psychiatry Cogn Neurosci Neuroimaging*. (Epub 2019 Jul 25). PMID: 31543456
156. Bodkin JA, Coleman MJ, Godfrey LJ, Carvalho CMB, Morgan CJ, Suckow RF, Anderson T, **Öngür D**, Kaufman MJ, Lewandowski KE, Siegel AJ, Waldstreicher E, Grochowski CM, Javitt DC, Rujescu D, Hebring S, Weinsilboum R, Rodriguez SB, Kirchoff C, Visscher T, Vuckovic A, Fialkowski A, McCarthy S, Malhotra D, Sebat J, Goff DC, Hudson JI, Lupski JR, Coyle JT, Rudolph U, Levy DL. (2019) Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene. *Biol Psychiatry*. 86(7):523-535. PMID: 31279534
157. Maher S, Ekstrom T, **Öngür D**, Levy DL, Norton DJ, Nickerson LD, Chen Y. (2019) Functional disconnection between the visual cortex and right fusiform face area in schizophrenia. *Schizophr Res*. 209:72-79. PMID: 31126803
158. Hwang J, DeLisi LE, **Öngür D**, Riley C, Zuo C, Shi X, Sung YH, Kondo D, Kim TS, Villafuerte R, Smedberg D, Yurgelun-Todd D, Renshaw PF. (2019) Cerebral bioenergetic differences measured by phosphorus-31 magnetic resonance spectroscopy between bipolar disorder and healthy subjects living in two different regions suggesting possible effects of altitude. *Psychiatry Clin Neurosci*. 73(9):581-589. PMID: 31125152
159. Monaghan CK, Brickman S, Huynh P, **Öngür D**, Hall MH. (2019) A longitudinal study of event related potentials and correlations with psychosocial functioning and clinical features in first episode psychosis patients. *Int J Psychophysiol*. 145:48-56. PMID: 31108121
160. Cawkwell PB, Bolton KW, Karmacharya R, **Öngür D**, Shinn AK. (2020) Two-year diagnostic stability in a real-world sample of individuals with early psychosis. *Early Interv Psychiatry*. 2020 Feb 10. PMID: 32043313
161. Yapıcı Eser H, Taşkiran AS, Ertınmaz B, Mutluer T, Kılıç Ö, Özcan Morey A, Necef I, Yalçınay İnan M, **Öngür D**. (2020) Anxiety disorders comorbidity in pediatric bipolar disorder: a meta-analysis and meta-regression study. *Acta Psychiatr Scand*. 2020 Jan 3. PMID: 31899546

162. Baytunca MB, Öngür D. (2020) Plasma spermine levels in patients with schizophrenia and bipolar disorder: A preliminary study. *Schizophr Res.* 2019 Dec 3. PMID: 31806521
163. Whiffin, N., Armean, I. M., Kleinman, A., Marshall, J. L., Minikel, E. V., Goodrich, J. K., Quaipe, N. M., Cole, J. B., Wang, Q., Karczewski, K. J., Cummings, B. B., Francioli, L., Laricchia, K., Guan, A., Alipanahi, B., Morrison, P., Baptista, M., Merchant, K. M., Genome Aggregation Database Production Team, Genome Aggregation Database Consortium, MacArthur, D. G. (2020). The effect of LRRK2 loss-of-function variants in humans. *Nature medicine*, 2020 May 27. PMID: 32461697 (Listed as “Collaborator” in 6 related papers; only one listed here)
164. Erkol C, Cohen T, Chouinard VA, Lewandowski KE, Du F, **Öngür D.** (2020) White Matter Measures and Cognition in Schizophrenia. *Front Psychiatry.* (Epub 2020 Jul 10);11:603. PMID: 32765308
165. Chan SY, Brady R, Hwang M, Higgins A, Nielsen K, **Öngür D,** Hall MH. (2020) Heterogeneity of Outcomes and Network Connectivity in Early-Stage Psychosis: A Longitudinal Study. *Schizophr Bull.* (Epub 2020 Jun 23) PMID: 32572485
166. Shinn AK, Cawkwell PB, Bolton K, Healy BC, Karmacharya R, Yip AG, **Öngür D,** Pinder-Amaker S. (2020) Return to College After a First Episode of Psychosis. *Schizophr Bull Open.* 2020 Jan;1(1):sgaa041. PMID: 32984820
167. Yuan J, Song X, Kuan E, Wang S, Zuo L, **Öngür D,** Hu W, Du F. The structural basis for interhemispheric functional connectivity: Evidence from individuals with agenesis of the corpus callosum. *Neuroimage Clin.* (Epub 2020 Sep 15). PMID: 32979843
168. Szmulewicz AG, Benson NM, Hsu J, Hernán MA, **Öngür D.** (2021) Effects of COVID-19 pandemic on mental health outcomes in a cohort of early psychosis patients. *Early Interv Psychiatry.* (Epub 2021 Jan 11). PMID: 33432786
169. Baytunca MB, de Frederick B, Bolat GU, Kardas B, Inci SB, Ipci M, Calli C, Özyurt O, **Öngür D,** Süren S, Ercan ES. (2021) Increased cerebral blood flow in the right anterior cingulate cortex and fronto-orbital cortex during go/no-go task in children with ADHD. *Nord J Psychiatry.* (Epub 2021 Jan 7). PMID: 33411645
170. Song X, Chen X, Yuksel C, Yuan J, Pizzagalli DA, Forester B, **Öngür D,** Du F. (2021) Bioenergetics and abnormal functional connectivity in psychotic disorders. *Mol Psychiatry.* (Epub 2021 Jan 4). PMID: 33398087
171. Li Z, Huang J, Hung KSY, Deng Y, Wang Y, Wang Y, Lui SSY, Mak HKF, Sham PC, Cheung EFC, **Öngür D,** Dazzan P, Chan RCK. (2021) Cerebellar hypoactivation is associated with impaired sensory integration in schizophrenia. *J Abnorm Psychol.* 130(1):102-111. PMID: 33074697

172. Yuksel C, Chen X, Chouinard VA, Nickerson LD, Gardner M, Cohen T, **Öngür D**, Du F. (2021) Abnormal Brain Bioenergetics in First-Episode Psychosis. *Schizophr Bull Open* (Epub 2021 Jan 30);2(1):sgaa073. PMID: 33554120
173. Johnson KA, Guyer M, **Öngür D**, Friedman-Yakoobian M, Kline E, Carol E, Davis B, Keshavan M. (2021) Early intervention in psychosis: Building a strategic roadmap for Massachusetts. *Schizophr Res.* (Epub 2021 Mar); 229:43-45. PMID: 33611222
174. Merritt K, McGuire PK, Egerton A; 1H-MRS in Schizophrenia Investigators, Aleman A, Block W, Bloemen OJN, Borgan F, Bustillo JR, Capizzano AA, Coughlin JM, De la Fuente-Sandoval C, Demjaha A, Dempster K, Do KQ, Du F, Falkai P, Galinska-Skok B, Gallinat J, Gasparovic C, Ginestet CE, Goto N, Graff-Guerrero A, Ho BC, Howes OD, Jauhar S, Jeon P, Kato T, Kaufmann CA, Kegeles LS, Keshavan M, Kim SY, Kunugi H, Lauriello J, Liemburg EJ, Mcilwain ME, Modinos G, Mouchlianitis ED, Nakamura J, Nenadic I, **Öngür D**, Ota M, Palaniyappan L, Pantelis C, Plitman E, Posporelis S, Purdon SE, Reichenbach JR, Renshaw PF, Russell BR, Sawa A, Schaefer M, Shungu DC, Smesny S, Stanley JA, Stone JM, Szulc A, Taylor R, Thakkar K, Théberge J, Tibbo PG, van Amelsvoort T, Walecki J, Williamson PC, Wood SJ, Xin L, Yamasue H. (2021) Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data. *JAMA Psychiatry.* (Epub 2021 Jun 1); 78(6):667-681. PMID: 33881460
175. Kuan E, Chen X, Du F, **Öngür D**. (2021) N-acetylaspartate concentration in psychotic disorders: T2-relaxation effects. *Schizophr Res.* (Epub 2021 May 17); 232:42-44. PMID: 34015554
176. **Öngür D**, Price M, Malekani M, Heinrich H, Prete S, Singer DE, Lewis E, Hsu J. (2021) Creatine kinase levels among asymptomatic patients with severe mental illnesses: A complex baseline for an important clinical biomarker. *Schizophr Res.* (Epub 2021 May 20); 232:85-86. PMID: 34023581
177. Cooper JA, Nuutinen MR, Lawlor VM, DeVries BAM, Barrick EM, Hossein S, Cole DJ, Leonard CV, Hahn EC, Teer AP, Shields GS, Slavich GM, **Öngür D**, Jensen JE, Du F, Pizzagalli DA, Treadway MT. (2021) Reduced adaptation of glutamatergic stress response is associated with pessimistic expectations in depression. *Nat Commun.* (Epub 2021 May 26); 12(1):3166. PMID: 34039978
178. Prescott A, Huber R, Kanekar S, Kondo D, Prisciandaro J, **Öngür D**, Renshaw PF. (2021) Effect of moderate altitude on human cerebral metabolite levels: A preliminary, multi-site, proton magnetic resonance spectroscopy investigation. *Psychiatry Res Neuroimaging.* (Epub 2021 Jun 2); PMID: 34098247

179. Norton DJ, McBain RK, Murray GE, Khang J, Zong Z, Bollacke HR, Maher S, Levy DL, **Öngür D**, Chen Y. (2021) Normal Face Detection Over a Range of Luminance Contrasts in Adolescents With Autism Spectrum Disorder. *Front Psychol.* (Epub 2021 Jul 16); PMID: 34335378
180. Szmulewicz A, **Öngür D**, Shinn AK, Carol EE, Dow J, Yilmaz N, Durning PT, Sastry JM, Hsu J. (2021) Impact of the COVID-19 Pandemic on the Employment and Educational Outcomes of Individuals in a First-Episode Psychosis Clinic. *Psychiatr Serv.* (Epub 2021 Jun 30); PMID: 34189932
181. Girard JM, Vail AK, Liebenthal E, Brown K, Kilciksiz CM, Pennant L, Liebson E, **Öngür D**, Morency LP, Baker JT. (2021) Computational analysis of spoken language in acute psychosis and mania. *Schizophr Res.* (Epub 2021 Aug 26); PMID: 34456131
182. Kline ER, Johnson KA, Szmulewicz A, Davis BJ, Sanders AS, Friedman-Yakoobian M, **Öngür D**, Stepanyk M, Williamson AN, Guyer M, Keshavan M. (2021) "Real-world" first-episode psychosis care in Massachusetts: Lessons learned from a pilot implementation of harmonized data collection. *Early Interv Psychiatry.* (Epub 2021 Aug 28); PMID: 34453486
183. Chan SY, Brady RO, Lewandowski KE, Higgins A, **Öngür D**, Hall MH. (2021) Dynamic and progressive changes in thalamic functional connectivity over the first five years of psychosis. *Mol Psychiatry.* (Epub 2021 Oct 25); PMID: 34697450
184. Yüksel M, Murphy M, Rippe J, Leicht G, **Öngür D**. (2021) Decreased mismatch negativity and elevated frontal-lateral connectivity in first-episode psychosis. *J Psychiatr Res.* (Epub 2021 Sep 23); 144:37-44. PMID: 34592510
185. Cohen BM, Ravichandran C, **Öngür D**, Harris PQ, Babb SM. (2021) Use of DSM-5 diagnoses vs. other clinical information by US academic-affiliated psychiatrists in assessing and treating psychotic disorders. *World Psychiatry.* 20(3):447-448. PMID: 34505361
186. Wood AJ, Carroll AR, Shinn AK, **Öngür D**, Lewandowski KE. (2021) Diagnostic Stability of Primary Psychotic Disorders in a Research Sample. *Front Psychiatry.* (Epub 2021 Oct 28). PMID: 34777044
187. Stone LMD, Millman ZB, **Öngür D**, Shinn AK. (2021) The Intersection Between Childhood Trauma, the COVID-19 Pandemic, and Trauma-related and Psychotic Symptoms in People With Psychotic Disorders. *Schizophr Bull Open.* (Epub 2021 Nov 10) PMID: 34881362
188. Hwang M, Roh YS, Talero J, Cohen BM, Baker JT, Brady RO, **Öngür D**, Shinn AK. (2021) Auditory hallucinations across the psychosis spectrum: Evidence of

dysconnectivity involving cerebellar and temporal lobe regions. *Neuroimage Clin.* (Epub 2021 Nov 24). PMID: 34911197.

189. Chen X, Fan X, Song X, Gardner M, Du F, **Öngür D.** (2022) White Matter Metabolite Relaxation and Diffusion Abnormalities in First-Episode Psychosis: A Longitudinal Study. *Schizophr Bull.* (Epub 2022 Jan 6) PMID: 34999898
190. Moran LV, Tsang ES, **Öngür D,** Hsu J, Choi MY. (2022) Geographical variation in hospitalization for psychosis associated with cannabis use and cannabis legalization in the United States: *Psychiatry Res.* (Epub 2022 Jan 4). PMID: 35016118
191. Murphy M, Fedele SJ, **Öngür D.** (2022) WellSpace: Peer-led groups for first-episode psychosis before and during the COVID era. *Early Interv Psychiatry.* (Epub 2022 Jan 31) PMID: 35100660
192. Benson NM, Yang Z, Weiss M, Fung V, Moran LV, **Öngür D,** Hsu J. (2022) Identifying Diagnoses of Schizophrenia Spectrum Disorder in Large Data Sets. *Psychiatr Serv.* (Epub 2022 Apr 20). PMID: 35440163
193. Singh T, Poterba T, Curtis D, Akil H, Al Eissa M, Barchas JD, Bass N, Bigdeli TB, Breen G, Bromet EJ, Buckley PF, Bunney WE, Bybjerg-Grauholm J, Byerley WF, Chapman SB, Chen WJ, Churchhouse C, Craddock N, Cusick CM, DeLisi L, Dodge S, Escamilla MA, Eskelinen S, Fanous AH, Faraone SV, Fiorentino A, Francioli L, Gabriel SB, Gage D, Gagliano Taliun SA, Ganna A, Genovese G, Glahn DC, Grove J, Hall MH, Hämläinen E, Heyne HO, Holi M, Hougaard DM, Howrigan DP, Huang H, Hwu HG, Kahn RS, Kang HM, Karczewski KJ, Kirov G, Knowles JA, Lee FS, Lehrer DS, Lescai F, Malaspina D, Marder SR, McCarroll SA, McIntosh AM, Medeiros H, Milani L, Morley CP, Morris DW, Mortensen PB, Myers RM, Nordentoft M, O'Brien NL, Olivares AM, **Öngür D,** Ouwehand WH, Palmer DS, Paunio T, Quedsted D, Rapaport MH, Rees E, Rollins B, Satterstrom FK, Schatzberg A, Scolnick E, Scott LJ, Sharp SI, Sklar P, Smoller JW, Sobell JL, Solomonson M, Stahl EA, Stevens CR, Suvisaari J, Tiao G, Watson SJ, Watts NA, Blackwood DH, Børglum AD, Cohen BM, Corvin AP, Esko T, Freimer NB, Glatt SJ, Hultman CM, McQuillin A, Palotie A, Pato CN, Pato MT, Pulver AE, St Clair D, Tsuang MT, Vawter MP, Walters JT, Werge TM, Ophoff RA, Sullivan PF, Owen MJ, Boehnke M, O'Donovan MC, Neale BM, Daly MJ. (2022) Rare coding variants in ten genes confer substantial risk for schizophrenia. *Nature.* 604(7906):509-516. PMID: 35396579
194. Chan SY, Nickerson LD, Pathak R, **Öngür D,** Hall MH. (2022) Impact of Substance Use Disorder on Between-Network Brain Connectivity in Early Psychosis. *Schizophr Bull Open.* (Epub 2022 Jan 27) PMID: 35386953
195. Murphy M, **Öngür D.** (2022) Thought disorder is correlated with atypical spoken binomial orderings. *NPJ Schizophr.* 8(1):25. PMID: 35304875

196. Sharpe V, Schoot L, Lewandowski KE, Öngür D, Türközer HB, Hasoğlu T, Kuperberg GR. (2022) We both say tomato: Intact lexical alignment in schizophrenia and bipolar disorder. *Schizophr Res.* 243:138-146. PMID: 35290874
197. Di Biase MA, Geaghan MP, Reay WR, Seidlitz J, Weickert CS, Pébay A, Green MJ, Quidé Y, Atkins JR, Coleman MJ, Bouix S, Knyazhanskaya EE, Lyall AE, Pasternak O, Kubicki M, Rathi Y, Visco A, Gaunnac M, Lv J, Mesholam-Gately RI, Lewandowski KE, Holt DJ, Keshavan MS, Pantelis C, **Öngür D**, Breier A, Cairns MJ, Shenton ME, Zalesky A. (2022) Cell type-specific manifestations of cortical thickness heterogeneity in schizophrenia. *Mol Psychiatry.* 27(4):2052-2060. PMID: 35145230

Peer-reviewed review articles

1. **Öngür D**, Price JL (2000) The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans. *Cereb. Cortex* **10**:206-219.
2. Papakostas GI, **Öngür D**, Mischoulon D, Fava M (2004) Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses. *European Neuropsychopharmacology.* **14**: 135-42.
3. **Öngür D**, Heckers S (2004) A role for glia in the action of electroconvulsive therapy. *Harvard Rev. Psych.* **12**: 253-62.
4. Sim K, Cullen TJ, **Öngür D**, Heckers S (2006) Testing models of thalamic dysfunction in schizophrenia using neuroimaging. *J. Neural Transm.* **113**: 907-28
5. Lewandowski KE, Cohen BM, **Öngür D** (2010) Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. *Psychol Med.* **41**: 225-41
6. Yuksel C, **Öngür D** (2010) Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. *Biol Psychiatry* **68**:785-94
7. Stoklosa J, **Öngür D** (2011) Choosing an antipsychotic in the post-second generation antipsychotic age. *Harvard Rev. Psych.* 19:271-6.
8. Potuzak M, Ravihandran C, Lewandowski KE, **Öngür D**, Cohen BM (2012) Categorical vs. dimensional classification of psychotic disorders. *Compr Psychiatry* 53:1118-29.
9. Du F, **Öngür D** (2013) Probing myelin and axon abnormalities separately in psychiatric disorders using MRI techniques. *Front Integr Neurosci.* 11;7:24.
10. Brady R Jr, **Öngür D**, Keshavan M (2014) Neurobiology of mood-state shifts in bipolar disorder: a selective review and a hypothesis. *Harv Rev Psychiatry.* 22(1):23-30.

11. **Öngür D**, Bechtholt AJ, Carlezon WA Jr, Cohen BM (2014) Glial abnormalities in mood disorders. *Harvard Rev. Psychiatry.* 22(6):334-7.
12. Arat HE, Chouinard VA, Cohen BM, Lewandowski KE, **Öngür D** (2015) Diffusion tensor imaging in first degree relatives of schizophrenia and bipolar disorder patients. *Schizophr Res.* 161(2-3):329-339.
13. Yuksel AC, Tegin C, O'Connor L, Du F, Ahat HE, Cohen BM, **Öngür D** (2015) Phosphorus magnetic resonance spectroscopy studies in schizophrenia. *J Psychiatr Res.* 68:157-66.
14. Wang X, **Öngür D**, Auerbach RP, Yao S. (2016) Cognitive Vulnerability to Major Depression: View from the Intrinsic Network and Cross-network Interactions. *Harv Rev Psychiatry.* 24(3):188-201.
15. Kani AS, Shinn AK, Lewandowski KE, **Öngür D**. (2016) Converging effects of diverse treatment modalities on frontal cortex in schizophrenia: A review of longitudinal functional magnetic resonance imaging studies. *J Psychiatr Res.* 84:256-276. PMID:27776293
16. Dogan AE, Yuksel C, Du F, Chouinard VA, **Öngür D**. (2018) Brain lactate and pH in schizophrenia and bipolar disorder: a systematic review of findings from magnetic resonance studies. *Neuropsychopharmacology.* (Epub 2018 Mar 14) PMID: 29581538
17. Kılıksız CM, **Öngür D**. (2019) Double-Dissociation Studies in Psychiatric Research: A Scoping Review. *Harv Rev Psychiatry.* 2019 Nov/Dec;27(6):336-341. PMID: 31714464
18. **Öngür D**, Carter CS, Gur RE, Perkins D, Sawa A, Seidman LJ, Tamminga C, Huggins W, Hamilton C. (2019) Common Data Elements for National Institute of Mental Health-Funded Translational Early Psychosis Research. *Biol Psychiatry Cogn Neurosci Neuroimaging.* (Epub 2019 Jun 29) PMID:31439493
19. Türközer HB, **Öngür D**. (2020) A projection for psychiatry in the post-COVID-19 era: potential trends, challenges, and directions. *Mol Psychiatry.* (Epub 2020 Jul 17)
20. Cohen BM, **Öngür D**, Babb SM. (2021) Alternative Diagnostic Models of the Psychotic Disorders: Evidence-Based Choices. *Psychother Psychosom.* (Epub 2021 Jul 7) PMID: 34233335
21. Song T, Song X, Zhu C, Patrick R, Skurla M, Santangelo I, Green M, Harper D, Ren B, Forester BP, **Öngür D**, Du F. (2021) Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer's disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies. *Ageing Res Rev.* (Epub 2021 Oct 29). PMID: 34751136

22. Cay M, Gonzalez-Heydrich J, Teicher MH, van der Heijden H, **Öngür D**, Shinn AK, Upadhyay J. (2022) Childhood maltreatment and its role in the development of pain and psychopathology. *Lancet Child Adolesc Health*. (Epub 2022 Jan 27) PMID: 35093193

Non-peer reviewed publications in print or other media

Reviews, Chapters, Editorials

1. **Öngür D** (2006) An approach to the patient with schizophrenia and other psychotic disorders: delusions, hallucinations, disorganized speech, or grossly disorganized behavior. In “The ten-minute guide to psychiatric diagnosis and treatment”, Ed. T.A. Stern. Professional Publishing Group, New York, NY
2. **Öngür D** (2006) Commentary on “Obsessive compulsive symptoms in schizophrenia: frequency and clinical features” by Byerly et al. *Evidence Based Mental Health* **9**: 28
3. **Öngür D** (2007) Introduction to the special issue on schizophrenia. *Harvard Rev. Psych.* **15**: 187-8
4. Holt D, **Öngür D**, Wright CI, Dickerson BC, Rauch SL (2008) Neuroanatomical systems relevant to neuropsychiatric disorders. In “Comprehensive Clinical Psychiatry”, Eds. T.A. Stern, J.F. Rosenbaum, M. Fava, J. Biederman, S.L. Rauch. Mosby Inc., Philadelphia, PA
5. **Öngür D** (2011) Book review of “Antipsychotic Trials in Schizophrenia: the CATIE project” eds. Lieberman and Stroup. *Am. J. Psych.* **168**: 334
6. **Öngür D** (2013) Making Progress With Magnetic Resonance Spectroscopy. *JAMA Psychiatry* **70**:1265-6.
7. Heckers S, Woodward N, **Öngür D** (2013) Neuroimaging studies of psychotic disorders. In “Neurobiology of Mental Illness”, 4th Edition, Eds. D.S. Charney, J.D. Buxbaum, P. Sklar, E.J. Nestler. Oxford University Press.
8. Keshavan MS, **Öngür D** (2014) The journey from RDC/DSM diagnoses toward RDoC dimensions. *World Psychiatry*. **13**(1):44-6.
9. **Öngür D**, Yildiz A (2014) Introduction to the special issue on Bipolar Disorder. *Harvard Rev. Psych.* **22**(6):325.
10. Lokko HN, **Öngür D**, Gunderson JG, Chen JA (2016) Ambivalence About Recovery in a Case of Psychotic Illness: Diagnostic, Treatment, and Cultural Challenges. *Harv. Rev. Psych.* **24**(1):61-8.
11. Krystal JH, Abi-Dargham A, Akbarian S, Arnsten AF, Barch DM, Bearden CE, Braff DL, Brown ES, Bullmore ET, Carlezon WA Jr, Carter CS, Cook EH Jr, Daskalakis ZJ, DiLeone RJ, Duman RS, Grace AA, Hariri AR, Harrison PJ, Hiroi N, Kenny PJ, Kleinman JE, Krystal AD, Lewis DA, Lipska BK, Marder SR, Mason GF, Mathalon DH,

- McClung CA, McDougle CJ, McIntosh AM, McMahon FJ, Mirnics K, Monteggia LM, Narendran R, Nestler EJ, Neumeister A, O'Donovan MC, **Öngür D**, Pariante CM, Paulus MP, Pearlson G, Phillips ML, Pine DS, Pizzagalli DA, Pletnikov MV, Ragland JD, Rapoport JL, Ressler KJ, Russo SJ, Sanacora G, Sawa A, Schatzberg AF, Shaham Y, Shamay-Tsoory SG, Sklar P, State MW, Stein MB, Strakowski SM, Taylor SF, Turecki G, Turetsky BI, Weissman MM, Zachariou V, Zarate CA Jr, Zubieta JK. (2016) Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. *Biol Psychiatry*. 80(2):84-6. PMID: 27346079
12. **Öngür D**. (2017) Systems Research in Psychiatric Neuroscience. *JAMA Psychiatry*. (Epub 2017 Apr 26). PMID: 28445562
 13. Lewandowski KE, **Öngür D**, Keshavan MS. (2017) Development of novel behavioral interventions in an experimental therapeutics world: Challenges, and directions for the future. *Schizophr Res*. (Epub 2017 Jun 16). PMID: 28629888
 14. Konradi C, **Öngür D**. (2017) Role of mitochondria and energy metabolism in schizophrenia and psychotic disorders. *Schizophr Res*. (Epub 2017 Jul 10). PMID: 28705531
 15. **Öngür D**. (2017) Dopamine Dysfunction in Schizophrenia and Bipolar Disorder-Never the Twain Shall Meet? *JAMA Psychiatry*. (Epub 2017 Oct 11). PMID: 29049431
 16. **Öngür D**, Heckers S. (2018) JAMA Psychiatry-The Year in Review, 2017. *JAMA Psychiatry*. (Epub 2018 Mar 14). PMID: 29541746
 17. **Öngür D**. (2018) Transitions in JAMA Psychiatry. *JAMA Psychiatry*. 75(7):667-668. PMID: 29955784
 18. Cohen BM, **Öngür D**. (2018) The urgent need for more research on bipolar depression. *Lancet Psychiatry*. 5(12):e29-e30. PMID: 30477660
 19. **Öngür D**. (2019) JAMA Psychiatry-The Year in Review, 2018. *JAMA Psychiatry*. [Epub 2019 Mar 20] PMID: 30892560
 20. **Öngür D**. (2019) Introducing JAMA Network Insights. *JAMA Psychiatry*. 76(7):675. PMID: 31090873
 21. **Öngür D**. (2019) Focusing on the Biological System Instead of the Biological Level in Psychiatry Research. *Harv Rev Psychiatry*. 27(6):333-335. PMID: 31714463
 22. **Öngür D**. (2019) Celebrating the 100th Anniversary of the Archives of Neurology and Psychiatry. *JAMA Psychiatry*. (Epub 2019 Sep 19). PMID: 31536107
 23. **Öngür D**. (2019) Challenges When Conducting Complex Clinical Research. *JAMA Psychiatry*. (Epub 2019 Jul 31). PMID: 31365034
 24. **Öngür D** (2020) Magnetic Resonance Spectroscopy Studies in Schizophrenia. In "Neuroimaging in Schizophrenia", Eds. M. Kubicki, M.E. Shenton. Springer.

25. Bauchner H, **Öngür D.** (2020) Notice of Retractions: "Association of Posttraumatic Stress Disorder With Reduced In Vivo Norepinephrine Transporter Availability in the Locus Coeruleus" and "Association of In Vivo κ -Opioid Receptor Availability and the Transdiagnostic Dimensional Expression of Trauma-Related Psychopathology" by Alexander Neumeister. *JAMA Psychiatry*. 2020 Feb 19. PMID: 32074384
26. Shah JL, Allen NB, Avenevoli S, Correll CU, Fisher HL, Hickie IB, Luna B, **Öngür D,** Yung AR (2020) A developmentally informed approach to characterizing, staging, and intervening in youth mental health problems. In "Youth Mental Health: A Paradigm for Prevention and Early Intervention", Eds. P.J. Uhlhaas and S.J. Wood. Ernst Strungmann Forum Publications, MIT Press
27. **Öngür D,** Bauchner H (2020) Notice of Retraction: Maslej et al. Individual Differences in Response to Antidepressants: A Meta-analysis of Placebo-Controlled Randomized Clinical Trials. *JAMA Psychiatry*. (Epub 2020 Jun 10) PMID: 32520998
28. Murphy M, **Öngür D.** (2020) EEG microstate sequences suggest abnormally chaotic brain dynamics in psychosis. *Neuropsychopharmacology*. (Epub 2020 Aug 14) PMID: 32796920
29. **Öngür D,** Perlis R, Goff D. (2020) Psychiatry and COVID-19. *JAMA*. (Epub 2020 Sep 22); 324(12):1149-1150. PMID: 32960247
30. Du G, **Öngür D** (2021) Neuroimaging Studies in Bipolar Disorder and Schizophrenia. In "Bipolar Brain", Ed. S. Strakowski. Oxford University Press.
31. **Öngür D,** Benes F, Freudenreich O, Keshavan M, McCarley R (2021) Schizophrenia Spectrum and Other Psychotic Disorders. In "Introduction to Psychiatry", Eds. J. Alpert, S. Schlozman, and A. Walker. Cambridge University Press.
32. **Öngür D.** (2021) JAMA Psychiatry-The Year in Review, 2020. *JAMA Psychiatry*. (Epub 2021 May 1);78(5):475-476. PMID: 33760055.
33. Fontanarosa PB, Flanagin A, Ayanian JZ, Bonow RO, Bressler NM, Christakis D, Disis ML, Josephson SA, Kibbe MR, **Öngür D,** Piccirillo JF, Redberg RF, Rivara FP, Shinkai K, Yancy CW (2021) Equity and the JAMA Network. *JAMA*. (Epub 2021 Jun 3). PMID: 34081100. **NOTE:** This article appeared simultaneously in identical form in 12 JAMA Network journals.
34. Coyle JT, **Öngür D.** (2021) In Memoriam: James C. Harris, MD. *JAMA Psychiatry*. (Epub 2021 Jun 16); PMID: 34132763
35. **Öngür D.** (2021) Considerations in Publishing a Psychiatric Randomized Clinical Trial With Kenyan Children. *JAMA Psychiatry*. (Epub 2021 Aug 1); 78(8):837-838. PMID: 34106224
36. **Öngür D.** (2021) JAMA Psychiatry Editorial Fellow. *JAMA Psychiatry*. (Epub 2021 Dec 14) PMID: 34905016

37. Cohen BM, **Öngür D**, Harris PQ. (2022) Past due: improving the naming of psychiatric disorders *Lancet Psychiatry*. (Epub 2022 Jan 6) PMID: 34998479
38. Dos Santos RG, Rossi GN, Hallak JEC, **Öngür D**, Dursun SM. (2022) Classical hallucinogens as antidepressant drugs: A cautionary approach. *Curr Neuropharmacol*. (Epub 2022 Apr 25). PMID: 35469569
39. **Öngür D**. (2022) JAMA Psychiatry-The Year in Review, 2021 *JAMA Psychiatry*. (Epub 2022 May 1);79(5):391-392. PMID: 35320346
40. Keshavan MS, Ongur D, Srihari VH. (2022) Toward an expanded and personalized approach to coordinated specialty care in early course psychoses. *Schizophr Res.*; 241:119-121. PMID: 35121436

Narrative Report

I have a background in neurobiology research and clinical psychiatry and I continue to weave these interests together in my work with patients with psychotic disorders (primarily schizophrenia, schizoaffective disorder, and bipolar disorder with psychosis). Following an NIMH K23 career development award, I have obtained R01s and an R21 from the NIMH focusing on clinical and biological research relevant to psychotic disorders. In recognition of my mentoring in patient oriented research, I have also been awarded a K24 award from NIMH. Although it varies over time, I currently spend approximately 80% of my time on research, and 20% on clinical administration and teaching.

I have an M.D./Ph.D. from the Washington University in St.Louis where I studied the neuroanatomy of the monkey prefrontal cortex in relation to visceral control and mood disorders in the laboratory of Dr. Joseph Price. I authored a review article summarizing my Ph.D. work and this paper has been cited over 1000 times to date. Following the end of my residency, I decided to focus on developing *in vivo* approaches to studying the neurobiology of psychiatric disorders. In this pursuit, I have primarily utilized proton magnetic resonance spectroscopy (MRS) to study brain metabolism and cellular function *in vivo* in schizophrenia and bipolar disorder. I have also combined this approach with structural and functional brain imaging to obtain convergent evidence of brain abnormalities in psychiatric conditions. Using proton MRS, I have studied the neurotransmitters glutamate and GABA as well as examined the diffusion of an intracellular metabolite, N-acetylaspartate (NAA). Over the years I have also had active collaborations with animal neuroscience groups at McLean Hospital, and this work led to animal neuroimaging studies which are currently supported by an R01 where I am PI. In addition to my neuroimaging work, I am PI on an internally-funded genotype-phenotype study of psychosis in collaboration with Drs. Bruce Cohen and Jordan Smoller and have published clinical phenotyping and genetics/neuroimaging combination papers from this study and these publications led to R21 funding. I am principally responsible for the design, execution and reporting of each of these projects. In my role as a clinical-translational researcher I collaborate with multiple other research groups at McLean, elsewhere at Harvard Medical School, and nationally.

Although most of my research has focused on neurobiology in psychiatric disorders, I maintain an active role in clinically oriented research, including descriptions of psychopathology

and phenomenology, but also clinical interventions to address unmet needs in our patients. I am contact PI on a multi-PI R01 studying a treatment regimen to reduce cardiovascular morbidity and mortality in patients taking antipsychotic medications.

I contribute to the research community in other ways. As of 7/1/2018 I was appointed as Editor in Chief of JAMA Psychiatry, a leading journal in the field. I also serve on the Editorial Board of several other journals. I have also served on committees at SOBP and ACNP, two leading professional organizations in psychiatry research. Finally, I was elected to the NARSAD Scientific Council, a body of about 150 leading psychiatric researchers which review grant applications for this prestigious philanthropic organization.

Following my residency training at the MGH/McLean Adult Psychiatry program (2000-2004), I have remained active in teaching and clinical administration along with my research. I continue to teach and supervise junior residents and medical students as well as mentor junior faculty in my research group. I have been awarded the Philip L. Isenberg teaching award, which is voted on by residents graduating from the program every year in 2007, the HMS Young Mentorship Award in 2010 and the Jonathan F. Borus Early Career Medical Student Teacher award from HMS Department of Psychiatry in 2011.

My clinical administrative responsibility expanded with my appointment in 2009 as Clinical Director of the Psychotic Disorders Division involving 2 inpatient units, a residential facility, and a specialty outpatient clinic (overall staff of 13 clinical psychiatrists and many additional staff members). Finally in 2012, I became Chief of the Psychotic Disorders Division, giving me responsibility over the research activities within the Division as well as clinical services. I also contribute to hospital-wide activities by serving on multiple committees.